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Atopic	   Dermatitis	   (AD)	   is	   recognized	   as	   one	   of	   the	   major	   worldwide	   health	  concerns.	   Despite	   being	   first	   described	   in	   the	   nineteenth	   century	   by	   Besnier,	  management	   options	   continue	   to	   be	   limited	   and	   are	   primarily	   palliative.	   AD	  patients	  are	  susceptible	  to	  many	  infections,	  such	  as	  the	  Herpes	  simplex	  virus	  (HSV),	  resulting	   in	   a	  more	   serious	   clinical	   subgroup	  of	  patients	  with	  AD	   complicated	  by	  Eczema	  Herpeticum	  (ADEH).	  
Supplementation	   with	   vitamin	   D	   (VD)	   has	   shown	   positive	   effects	   on	   the	   clinical	  outcome	  of	  AD	  in	  previous	  randomized	  controlled	  trials	  and	  clinical	  studies	  which	  could	  be	  due,	   in	  part,	   to	  the	  up	  regulation	  the	  antimicrobial	  peptide	  LL-­‐37,	  which	  has	  known	  antimicrobial,	  immune-­‐modulatory	  and	  wound	  healing	  effects.	  
Objective:	   We	   sought	   to	   determine	   the	   level	   of	   VD	   deficiency	   in	   AD	   and	   ADEH	  patients	   in	   a	   pediatric	   dermatology	   clinic,	   to	   investigate	   whether	   there	   was	   a	  difference	  in	  baseline	  VD	  levels	  between	  AD	  and	  ADEH,	  to	  examine	  skin	  surface	  LL-­‐37	   levels	   in	   both	   and	   to	   establish	   whether	   VD	   supplementation	   would	   result	   in	  clinical	  improvement.	  
Methods:	   A	   practice	   evaluation	   study	  was	   performed	   at	   the	   Sheffield	   Children’s	  Hospital.	   	  All	  AD	  patients	  were	  screened	  for	  VD	  deficiency.	  Those	  that	  were	  found	  deficient	  were	  assessed	  using	  SCORAD	  and	  POEM.	  Skin	  surface	  cells	  were	  collected	  from	  lesional	  and	  non-­‐lesional	  sites	  using	  a	  novel	  non-­‐invasive	  technique	  for	  LL-­‐37	  evaluation.	   In	   addition,	   serum	   IgE	   levels	   and	   serum	   calcium	   levels	  were	   also	  
	  
5	  
checked.	   Supplementation	   was	   then	   commenced	   for	   two	   months	   after	   which	  clinical	  severity	  was	  reassessed	  and	  all	  levels	  were	  rechecked.	  
Results:	  Ninety	  children	  (mean	  age	  9)	  were	  screened	  for	  VD	  deficiency;	  83	  %	  had	  low	   VD	   levels.	   VD	   levels	   were	   significantly	   lower	   in	   ADEH	   children	   than	   AD	  children	   (p	   <	   0.0001).	   Baseline	   SCORAD	   was	   also	   significantly	   higher	   in	   ADEH	  patients	  (p	  <	  0.0001).	  Skin	  surface	  LL-­‐37	  levels	  were	  reduced	  in	  ADEH	  patients	  in	  comparison	   to	  AD	  patients	   (p	  =	  0.46),	   and	  were	   significantly	   reduced	   in	  patients	  with	  severe	  AD	  (SCORAD>50)	   in	  comparison	  to	  patients	  with	  moderate	  (SCORAD	  25-­‐50)	   or	  mild	  AD	   (SCORAD	  <25;	  p=0.018).	  Two	  months	   of	   VD	   supplementation	  resulted	  in	  significant	  improvement	  of	  SCORAD	  (p	  <0.0001)	  and	  POEM	  (p	  <	  0.0001)	  in	  both	  groups;	  LL-­‐37	  levels	  also	  increased	  significantly	  (p	  =	  0.0004).	  
Conclusions:	  VD	  deficiency	  was	  found	  to	  be	  common	  in	  AD	  children,	  and	  VD	  supplementation	  reduced	  ADEH	  and	  AD	  severity	  in	  children.	  Part	  of	  the	  explanation	  is	  through	  increased	  LL-­‐37	  production.	  
Clinical	   implications:	  All	   AD	   patients	   should	   be	   screened	   for	   VD	   deficiency	   and	  supplemented	   accordingly,	   which	   has	   become	   routine	   clinical	   practice	   at	   the	  Sheffield	  Children’s	  Hospital.	  
	  
6	  




LIST	  OF	  FIGURES…………………………………………………………………………………………….…….9	  
LIST	  OF	  TABLES………………………………………………………………………………………………..…10	  
LIST	  OF	  ABBREVIATIONS………………………………………………………………………………….…….11	  
CHAPTER	  ONE:	  INTRODUCTION	  ..........................................................................................................	  14	  
I.	   CHAPTER	  ONE:	  INTRODUCTION	  ....................................................................................................	  15	  
I.I.	  Atopic	  Dermatitis	  .................................................................................................................	  15	  
I.II.	  Atopic	  Dermatitis	  complicated	  by	  Eczema	  Herpeticum	  (ADEH)	  ...................	  17	  
I.II	  Pathogenesis	  of	  AD:	  “Genes	  vs.	  Environment”	  .........................................................	  17	  
I.III	  The	  Epidermal	  Barrier	  .....................................................................................................	  20	  
I.III.I	  Epidermal	  differentiation	  .......................................................................................	  20	  
Cell-­‐cell	  adhesion	  in	  the	  epidermis	  ............................................................................	  23	  
I.III.II	  The	  epidermal	  barrier	  .............................................................................................	  25	  
A.	  Filaggrin	  “	  reinforcing	  the	  brick”	  .........................................................................	  27	  
B.	  Lipid	  lamellae	  “The	  mortar”	  ...................................................................................	  28	  
C.	  Corneodesmosomes	  “the	  iron	  rods”	  .....................................................................	  30	  
I.III.III	  The	  antimicrobial	  barrier	  ....................................................................................	  35	  
A.	  Skin	  Surface	  pH:	  ...........................................................................................................	  35	  
B.	  Antimicrobial	  peptides	  ..............................................................................................	  38	  
Cathelicidins	  ........................................................................................................................	  39	  
	  
7	  
Cathelicidin	  levels	  in	  AD	  patients	  ..............................................................................	  43	  
I.IV.	  Pathophysiology	  of	  AD	  ....................................................................................................	  44	  	   T	  regulatory	  cells…………………………………………………………………………..………..47	  
I.V	  Vitamin	  D	  and	  AD	  .................................................................................................................	  49	  
I.V.I	  VD	  Sources	  .......................................................................................................................	  50	  
I.V.II.	  Clinical	  manifestation	  of	  VD	  deficiency	  ............................................................	  51	  
I.V.III.	  VD	  and	  the	  Skin	  barrier	  .........................................................................................	  51	  
The	  effect	  of	  VD3	  on	  LL-­‐37	  .............................................................................................	  56	  
I.V.IV	  VD	  and	  the	  Innate	  Immune	  system	  ....................................................................	  57	  
I.V.V.	  VD	  and	  the	  Adaptive	  Immune	  System	  ...............................................................	  59	  
I.V.	  	  Aims	  of	  this	  study	  ...............................................................................................................	  61	  
II.	   CHAPTER	  TWO:	  MATERIALS	  AND	  METHODS	  ............................................................................	  63	  
II.I.	  	  Study	  design:	  ........................................................................................................................	  64	  
II.II	  Evaluation	  of	  clinical	  severity	  .......................................................................................	  66	  
I.II.I	  SCORAD	  .............................................................................................................................	  66	  
I.II.II	  The	  Patient	  Oriented	  Eczema	  Measure	  (POEM)	  ...........................................	  68	  
II.III.	  Evaluation	  of	  Cathelicidin	  levels	  (LL-­‐37)	  in	  the	  stratum	  corneum	  ............	  70	  
I.III.I	  Collection	  of	  superficial	  skin	  samples	  ................................................................	  70	  
I.III.II	  Analysis	  of	  LL-­‐37	  levels	  in	  superficial	  skin	  samples	  ...................................	  70	  
I.III.III	  The	  Bicinchoninic	  Acid	  (BCA)	  analysis	  ..........................................................	  74	  
II.IV.	  Statistical	  Analyses:	  ........................................................................................................	  76	  
III.	   CHAPTER	  THREE:	  RESULTS	  .......................................................................................................	  77	  
III.I.	  Patient	  demographics:	  ...............................................................................................	  78	  
III.II.	  Pre-­‐supplementation	  assessment:	  .......................................................................	  85	  
	  
8	  
III.III.	  Post-­‐supplementation	  assessment:	  ...................................................................	  97	  
IV.	   CHAPTER	  FOUR:	  DISCUSSION	  ..................................................................................................	  110	  
	   IV.I.	  Defining	  VD	  deficiency…...……………………………………………………………….111	  
	   IV.II.	  The	  selection	  of	  the	  appropriate	  VD	  supplementation……………………113	  
	   IV.III.	  The	  Genetics	  and	  Demographics	  of	  VD	  deficiency………………………….114	  
	   IV.IV.	  VD	  deficiency	  and	  AD…………………………………………………………………..	  115	  
V.	   FUTURE	  WORK:…………………………………………………………………………………………123	  
VI.	  REFERENCES………………………………………………………………………………………….124	  




LIST	  OF	  FIGURES:	  	  
Figure	  I.	  1:	  Layers	  of	  the	  Epidermis	  ...................................................................................................	  21	  
Figure	  I.	  2:	  Schematic	  diagram	  of	  the	  different	  junctions	  within	  the	  epidermis.	  ..........	  24	  
Figure	  I.	  3:	  Structure	  of	  the	  skin	  barrier.	  .........................................................................................	  26	  
Figure	  I.	  4:	  Lipid	  lamellae	  formation.	  ...............................................................................................	  29	  
Figure	  I.	  5:	  Defects	  identified	  in	  the	  skin	  barrier.	  ........................................................................	  33	  
Figure	  I.	  6:	  Importance	  of	  skin	  surface	  pH.	  .....................................................................................	  37	  
Figure	  I.	  7:	  AMP	  mechanism	  of	  actions.	  ...........................................................................................	  40	  
Figure	  I.	  8:	  The	  functions	  of	  LL-­‐37	  in	  the	  skin.	  ..............................................................................	  42	  
Figure	  I.	  9:	  Pathogenesis	  of	  AD.	  ...........................................................................................................	  45	  
Figure	  I.	  10:	  VD	  Production.	  ..................................................................................................................	  52	  
Figure	  I.	  11:	  Calcium	  gradient	  in	  the	  epidermis.	  ..........................................................................	  54	  
Figure	  I.	  12:	  The	  effect	  of	  VD3	  on	  the	  immune	  system.	  ...............................................................	  58	  
Figure	  II.	  1:	  SCORAD;	  extent	  of	  area	  involved	  in	  AD.	  .............................................................	  67	  
Figure	  II.	  2:	  POEM.	  .....................................................................................................................................	  69	  
Figure	  II.	  3:	  Overview	  of	  LL-­‐37	  ELISA	  Protocol.	  ...........................................................................	  73	  
Figure	  III.	  1:	  Flowchart	  of	  study.	  ....................................................................................................	  82	  
Figure	  III.	  2:	  VD	  levels	  in	  AD	  and	  ADEH	  children.	  ........................................................................	  86	  
Figure	  III.	  3:	  Classification	  of	  patients	  based	  on	  SCORAD.	  .......................................................	  87	  
Figure	  III.	  4:	  Correlation	  of	  SCORAD	  and	  VD	  levels.	  ...................................................................	  88	  
Figure	  III.	  5:	  SCORAD	  in	  AD	  and	  ADEH.	  ............................................................................................	  89	  
Figure	  III.	  6:	  POEM	  in	  AD	  and	  ADEH.	  ................................................................................................	  90	  
Figure	  III.	  7:	  LL-­‐37	  levels	  according	  to	  SCORAD.	  .........................................................................	  92	  
	  
10	  
Figure	  III.	  8:	  Lesional	  and	  non-­‐lesional	  LL-­‐37	  levels	  vs	  SCORAD.	  .........................................	  93	  
Figure	  III.	  9:	  LL-­‐37	  levels	  in	  AD	  and	  ADEH	  patients.	  ..................................................................	  95	  
Figure	  III.	  10:	  Lesional	  and	  Non-­‐lesional	  LL-­‐37	  levels	  in	  AD	  and	  ADEH.	  ...........................	  96	  
Figure	  III.	  11:	  	  Comparison	  of	  VD	  levels.	  ..........................................................................................	  98	  
Figure	  III.	  12:	  SCORAD	  after	  two	  months	  of	  VD	  supplements.	  ...............................................	  99	  
Figure	  III.	  13:	  SCORAD	  in	  AD	  and	  ADEH	  patients.	  .....................................................................	  100	  
Figure	  III.	  14:	  Stratification	  of	  SCORAD	  based	  upon	  type	  of	  VD	  supplement.	  ...............	  101	  
Figure	   III.	   15:	   The	   percentage	   of	   SCORAD	   reduction	   in	   OTC	   and	   Cholecalciferol	  
groups.	  ..........................................................................................................................................................	  103	  
Figure	  III.	  16:	  POEM	  scores	  after	  two	  months	  of	  VD	  supplements.	  ....................................	  104	  
Figure	  III.17:	  POEM	  scores	  in	  AD	  and	  ADEH	  patients.	  .............................................................	  105	  
Figure	  III.	  18:	  LL-­‐37	  levels	  in	  AD	  patients.	  ....................................................................................	  107	  
Figure	  III.	  19:	  Lesional	  and	  non-­‐lesional	  LL-­‐37	  levels	  in	  AD	  .................................................	  108	  




LIST	  OF	  TABLES:	  
	  
Table	  1.	  The	  different	  components	  involved	  in	  epidermal	  differentiation,	  and	  the	  
defects	  discovered	  in	  association	  with	  AD.	  .....................................................................................	  34	  
Table	  2:	  Concentration	  of	  Standards	  used	  in	  the	  Human	  LL-­‐37	  Elisa	  kit.	  ........................	  72	  
Table	  3:	  Concentrations	  of	  Standards	  used	  in	  the	  BCA	  assay	  .................................................	  75	  
Table	  4:	  Demographics	  of	  the	  AD	  patients	  screened	  in	  the	  clinic.	  ........................................	  79	  
Table	  5:	  Classification	  of	  VD	  status	  according	  to	  ethnic	  group	  in	  the	  population	  
screened.	  ........................................................................................................................................................	  80	  
Table	  6:	  Demographics	  of	  the	  AD	  patients	  included	  in	  the	  practice	  evaluation	  study.	  83	  
Table	  7:	  Classification	  of	  VD	  status	  according	  to	  ethnic	  group	  in	  the	  AD	  patients	  
included	  in	  the	  practice	  evaluation	  study.	  ......................................................................................	  84	  
	  
12	  
LIST	  OF	  ABBREVIATIONS:	  
	  
AD=	  Atopic	  Dermatitis	  ADEH=	  Atopic	  Dermatitis	  complicated	  by	  Eczema	  Herpeticum	  HSV=	  Herpes	  Simplex	  Virus	  VD=	  Vitamin	  D	  EASI=	  Eczema	  Area	  and	  Severity	  Index	  SCORAD=	  SCORing	  of	  AD	  POEM=	  Patient	  Oriented	  Eczema	  Measure	  K=	  Keratin	  SC=	  Stratum	  Corneum	  KLK=	  Kallikrien	  
SPINK-­‐5=	  Serine	  Protease	  Inhibitor	  Kazal-­‐5	  LEKTI=	  Lympho-­‐Epithilial	  Kazal-­‐Type	  Inhibitor	  AMP=	  Anti	  Microbial	  Peptide	  hCAP-­‐18=	  human	  Cationic	  Antimicrobial	  Peptide	  (inactive	  precursor)	  
S.	  aureus=	  Staphylococcus	  aureus	  LPS=	  Lipopolysaccharides	  TNF=	  Tumour	  Necrosis	  Factor	  TLR=	  Toll-­‐like	  Receptor	  PAMP=	  Pathogen	  Associated	  Molecular	  Patterns	  Tregs=	  Regulatory	  T	  lymphocytes	  TGF=	  Transforming	  Growth	  Factor	  DC=	  Dendritic	  cells	  VD2=	  Vitamin	  D2	  or	  ergocalciferol	  VD3=	  Viatmin	  D3,	  or	  cholecalciferol	  DBP=	  Vitamin	  D	  binding	  protien	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I. Chapter	  one:	  Introduction	  
	  
I.I.	  Atopic	  Dermatitis	  	  Atopic	   dermatitis	   (AD)	   is	   a	   common,	   persistent	   inflammatory	  disease	   of	   the	   skin	  with	  a	  prevalence	  of	  9-­‐20%	  worldwide	  (ISAAC	  1998).	   In	  Kuwait	   it	  affects	  31%	  of	  children	   (Nanda,	   Al-­‐Hasawi	   et	   al.	   1999).	   	   AD	   is	   characterized	   by	   dry,	   extremely	  pruritic	  skin,	  which	  causes	   the	  person	  to	  scratch.	  This	   leads	   to	   the	  appearance	  of	  erythematous	  scaly	  patches,	  excoriations	  and	  lichenification.	  AD	  severity	  can	  range	  from	  a	  few	  xerotic	  patches	  on	  the	  skin,	  to	  involvement	  of	  the	  whole	  body	  causing	  intense	   psychological	   distress.	   	   It	   is	   also	   typically	   very	   fluctuant	   in	   its	   course,	  rendering	  the	  diagnosis	  uncertain	  in	  some	  cases	  (Williams	  2000).	  
The	  location	  of	  the	  lesions	  in	  AD	  depends	  upon	  the	  age	  of	  the	  patient	  (Remitz	  and	  Reitamo	  2008).	  In	  infants,	  it	  affects	  predominantly	  the	  cheeks,	  wrists	  and	  extensor	  surfaces	  of	  the	  arms	  and	  legs.	  In	  older	  children,	  it	  is	  mainly	  seen	  on	  the	  ante-­‐cubital	  and	   popliteal	   fossae,	   as	   well	   as	   the	   nape	   of	   the	   neck.	   Peri-­‐oral	   and	   peri-­‐ocular	  involvement	   is	   also	   known	   to	   occur.	   Food	   allergies	   are	   found	   to	   be	   important	  triggers	   during	   infancy,	   whereas	   as	   the	   child	   gets	   older,	   other	   factors	   such	   as	  climate	  and	  stress	  become	  more	  important	  (Remitz	  and	  Reitamo	  2008).	  
In	  1980,	  Hanifin	  and	  Rajka	   introduced	  a	   series	  of	   criteria	   for	   the	  diagnosis	  of	  AD	  (Hanifin	  and	  Rajka	  1980).	  These	  consisted	  of	   four	  major	  criteria	  and	  over	  twenty	  minor	  ones.	   	   	  The	   list,	  however,	  contained	  invasive	  tests	  such	  as	  serum	  IgE	   levels	  and	  skin	  prick	  tests,	  and	  was	  therefore	   too	  complex	  to	  use	  on	  a	  daily	  basis.	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In	   1994,	   a	   refined	   list	   was	   agreed	   upon	   (Williams,	   Burney	   et	   al.	   1996),	   which	  proved	  to	  be	  easier	  for	  clinicians	  and	  epidemiological	  studies	  (Box	  1).	  
	  
	  
In	  order	  to	  qualify	  as	  a	  case	  of	  Atopic	  Dermatitis,	  a	  child	  must	  have:	  	  An	  itchy	  skin	  condition	  	  
Plus	  three	  or	  more	  of	  the	  following:	  1. Onset	  below	  the	  age	  of	  two	  2. History	  of	  flexural	  involvement	  3. History	  of	  dry	  skin	  4. Personal	  history	  of	  other	  atopic	  diseases	  or	  family	  history	  of	  first	  degree	  relative	  	  
Box	  1.	  The	  refined	  Hanifin	  and	  Rajka	  diagnostic	  criteria	  for	  Atopic	  Dermatitis.	  
	  
Over	   the	   years,	   many	   have	   suggested	   different	   diagnostic	   criteria	   and	   scoring	  systems	   for	   AD	   (Ricci,	   Dondi	   et	   al.	   2009).	   There	   are	   now	   more	   than	   twenty	  different	  scoring	  systems;	  the	  Nottingham	  Eczema	  Severity	  Score,	  Eczema	  Area	  and	  Severity	   Index	  (EASI),	  Severity	  Scoring	  of	  Atopic	  Dermatitis	   index	  (SCORAD),	  and	  Patient-­‐	  oriented	  Eczema	  Measure	  (POEM)	  are	  the	  most	  recognized	  (Williams	  and	  Grindlay	  2010).	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A	   recent	   study	  examined	  all	   these	   scoring	   systems,	  with	   the	   conclusion	   that	  only	  SCORAD,	  EASI	  and	  POEM	  are	  the	  only	  systems	  that	  have	  been	  tested	  sufficiently	  for	  use	  (Schmitt,	  Langan	  et	  al.	  2007).	  
	  
I.II.	  Atopic	  Dermatitis	  complicated	  by	  Eczema	  Herpeticum	  (ADEH)	  	  AD	   patients	   are	   particularly	   prone	   to	  many	   types	   of	   infections.	   One	   of	   the	  most	  prominent	  of	   these	   infections	   is	   the	  Herpes	  Simplex	  virus	  (HSV).	  This	  results	   in	  a	  subgroup	   of	   AD	   patients	   with	   Eczema	   Herpeticum	   (ADEH)	   presenting	   a	   more	  severe	   clinical	  manifestation	   (Beck,	  Boguniewicz	   et	   al.	   2009),	   and	   could	   be	  more	  challenging	  to	  diagnose	  and	  treat.	  
ADEH	  was	   first	   described	   in	   the	   19th	   century	   by	  Moritz	  Kaposi	   (Kaposi	   1887).	   It	  presents	   as	   a	   monomorphic,	   vesiculo-­‐papular	   eruption	   commonly	   affecting	   the	  head,	  trunk	  and	  neck	  (Wollenberg,	  Wetzel	  et	  al.	  2003).	  It	  can	  vary	  in	  severity	  from	  generalized	  body	  dissemination	  to	   few	  vesicular	  clusters,	   rendering	   the	  diagnosis	  difficult	   in	   some	   patients	   (Frisch	   and	   Siegfried	   2011).	   Complications	   of	   ADEH	  include	   kerato-­‐conjunctivitis,	   viremia	   and	   meningitis	   (Wollenberg,	   Wetzel	   et	   al.	  2003), and historically	  was	   associated with	   a 75	  %	  mortality	   rate	   before	   use	   of	  antiviral	  treatment	  (Sanderson,	  Brueton	  et	  al.	  1987).	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I.II	  Pathogenesis	  of	  AD:	  “Genes	  vs.	  Environment”	  
Genetic	   predisposition	   is	   undeniably	   an	   important	   factor	   for	   the	   development	   of	  AD.	   It	  seems	  to	  be	  responsible	   for	  25-­‐50%	  of	  one’s	  predisposition	  to	  develop	  AD,	  dependant	  upon	  whether	  single	  or	  multiple	  family	  members	  are	  involved	  (Williams	  2000).	   Indeed,	   some	   studies	   have	   shown	   that	   AD	   shows	   a	   monozygotic	  concordance	   rate	   of	   77%	   (Schultz	   Larsen	   1993),	   and	   as	   high	   as	   84.6%	   (Yilmaz-­‐Demirdag,	  Prather	  et	  al.	  2010).	  Dizygotic	  twins	  also	  show	  a	  strong	  concordance	  of	  62.5%	   (Yilmaz-­‐Demirdag,	   Prather	   et	   al.	   2010).	   Individuals	  were	   found	   to	   have	   a	  seven	  times	  increased	  risk	  of	  developing	  AD	  if	  a	  monozygotic	  sibling	  was	  affected;	  three	  times	  increase	  if	  dizygotic	  (Thomsen,	  Ulrik	  et	  al.	  2007).	  




The	   prevalence	   of	   AD,	   however,	   has	   increased	   meteorically	   within	   the	   past	   five	  decades.	  Studies	  show	  that	  the	  cumulative	  incidence	  of	  AD	  in	  children	  born	  before	  the	   year	   1960	   is	   less	   than	   three	  percent,	   a	   further	   increase	   to	   4-­‐8%	   for	   children	  born	   between	   1960-­‐1970,	   rising	   even	   more	   to	   over	   12%	   for	   children	   born	  afterwards	  (Williams	  2000).	  The	  ISAAC	  study	  identified	  the	  increase	  in	  atopy	  to	  be	  consistent	  worldwide,	   varying	   from	  0.3%	   to	   20.5%	   (ISAAC	  1998).	   In	  Kuwait,	   AD	  has	  an	  incidence	  of	  31%	  (Nanda,	  Al-­‐Hasawi	  et	  al.	  1999).	  Since	  genetics	  cannot	  have	  altered	   in	   those	   years	   to	   such	   an	   extent,	   scientists	   have	   turned	   to	   the	  environmental	  factors	  in	  an	  attempt	  to	  explain	  this	  increase.	  
Brunello	  Wuthrich	   first	   recognized	  and	  classified	  AD	   into	   two	  subtypes:	   extrinsic	  and	   intrinsic	   AD	   (Wuthrich,	   Cozzio	   et	   al.	   2007).	   Extrinsic	   AD	   was	   described	   as	  having	  elevated	   levels	  of	   total	   IgE,	  positive	   levels	  of	   specific	   IgE	   to	   common	  aero	  and	   food	   allergens,	   positive	   skin	   prick	   tests	   to	   these	   allergens,	   and	   respiratory	  involvement.	  Intrinsic	  AD	  was	  defined	  as	  having	  total	  IgE	  levels	  less	  than	  200	  kU/l,	  negative	   specific	   IgE	  and	   skin	  prick	   tests,	   and	  no	  asthma.	  This	   set	  off	   the	   eternal	  debate	   between	   allergists,	   scientists,	   and	   clinicians	   whether	   to	   regard	   these	  subtypes	   as	   two	   separate	   entities,	   or	   simply	   two	  phases	  within	   the	  AD	   spectrum	  (Bieber	  2010).	  
The	   latter	  was	  the	  conclusion	  reached	  by	  Folster-­‐Holst	  et	  al	   in	  Germany	  (Folster-­‐Holst,	  Pape	  et	  al.	  2006).	  Out	  of	  over	  200	  patients	  with	  AD,	  only	  18	  patients	  were	  found	   to	  have	   ‘intrinsic’	  AD.	   	  After	  a	  median	   follow	  up	  of	  7.5	  years,	   four	  of	   those	  patients	   also	   developed	   respiratory	   symptoms,	   although	   IgE	   levels	   did	   not	   rise	  above	  200	  kU/l.	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The	  World	  Allergy	  Organization	  recently	  defined	  atopy	  as	  being	  only	  in	  association	  with	   increased	   IgE	   levels	   (Johansson,	   Bieber	   et	   al.	   2004),	   thus	   they	   defined	   the	  extrinsic	  type	  to	  be	  “true	  AD”,	  and	  the	  intrinsic	  as	  “non-­‐atopic	  AD”	  (Bieber	  2010).	  In	  the	  small	  proportion	  that	  never	  progress	  to	  “true	  AD”,	  however,	  it	  is	  reasonable	  to	  believe	  that	  there	  is	  also	  an	  abnormality	  in	  the	  skin	  barrier	  that	  contributed	  to	  the	   manifestation	   of	   AD	   (Cork,	   Robinson	   et	   al.	   2006).	   This	   is	   reinforced	   by	   the	  finding	   that	   uninvolved	   skin	   in	   all	   AD	   patients,	   both	   true	   and	   non-­‐atopic,	   is	   still	  relatively	   thinner	   (White,	   Jenkinson	  et	  al.	  1987)	   than	  healthy	  people.	   In	  addition,	  the	  skin	  barrier	   still	  displays	  abnormal	  properties	  even	  after	   five	  years	  of	  having	  clear	  skin	  (Elias	  2008).	  
I.III	  The	  Epidermal	  Barrier	  
	  
I.III.I	  Epidermal	  differentiation	  
Epidermal	  thickness	  ranges	  from	  as	  thin	  as	  54	  μm	  in	  the	  eyelids,	  to	  637	  μm	  thick	  in	  the	  soles	  of	  the	  feet	  (Kusuma,	  Vuthoori	  et	  al.	  2010).	  The	  postauricular	  and	  popliteal	  fossae	  have	   also	  been	   found	   to	  be	   thin	   (Lee	   and	  Hwang	  2002;	  Cork,	  Danby	  et	   al.	  2008).	  Notably,	  these	  areas,	  with	  a	  naturally	  thin	  epidermis,	  are	  commonly	  affected	  in	  AD	  patients.	  






Figure	  I.	  1:	  Layers	  of	  the	  Epidermis	  As	   it	  migrates	   from	   the	   basal	   germinal	   layer	   (stratum	   basale),	   the	   keratinocyte	   changes	  from	   columnar	   and	   nuclear,	   gradually	   becoming	   polygonal	   and	   granular	   at	   the	   stratum	  granulosom	  level.	  (Candi,	  Schmidt	  et	  al.	  2005).	   	  Eventually	  it	  extrudes	  the	  nucleus,	  and	  at	  the	  stratum	  corneum	  (SC),	  the	  keratinocyte	  is	  anucleate	  and	  flat,	  becoming	  a	  “corneocyte”	  (Rito	  and	  Pineiro-­‐Maceira	  2009).	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Keratins	  5	  and	  14	  are	  the	  main	  structural	  proteins	  in	  the	  keratinocytes	  at	  the	  basal	  layer,	   and	   are	   organized	   into	   microfilaments.	   They	   are	   involved	   in	   forming	   the	  cytoskeleton	  of	  the	  cell,	  along	  with	  microtubules	  and	  microfilaments	  (actin)	  (Candi,	  Schmidt	  et	  al.	  2005).	  
As	   the	   keratinocyte	   differentiates,	   K5	   and	   14	   are	   replaced	   by	   K1	   and	   10	   at	   the	  stratum	   spinosom	   (Strelkov,	   Herrmann	   et	   al.	   2003).	   The	   structural	   protein	  involucrin	  is	  also	  synthesized	  at	  this	  level.	  At	  the	  stratum	  granulosum,	  loricrin	  and	  trichohyalin,	   along	   with	   the	   filaggrin	   precursor,	   profilaggrin	   are	   all	   synthesized	  (Bikle	   2012).	  Profilaggrin	   is	   subsequently	   cleaved	   to	   liberate	   filaggrin	  molecules	  (Chatterjea,	  Resing	  et	  al.	  2011),	  which	  then	  aggregates	  the	  keratin	  fibers	  into	  tight	  bundles	  at	  the	  stratum	  corneum	  (SC)	  level,	  changing	  the	  shape	  of	  the	  keratinocyte	  cell	  into	  a	  flat	  “corneocyte”	  (Kalinin,	  Marekov	  et	  al.	  2001).	  
In	  addition,	  the	  plasma	  membrane	  of	  the	  keratinocytes	  becomes	  reinforced	  at	  the	  SC	  level	  with	  the	  afore-­‐mentioned	  structural	  proteins,	  involucrin,	  trichohyalin	  and	  loricrin,	   which	   are	   then	   cross-­‐linked	   together	   with	   filaggrin,	   by	   enzymes	   called	  transglutaminases.	   This	   results	   in	   the	   formation	   of	   a	   tough,	   water	   impermeable	  case	  around	  the	  cell,	  referred	  to	  as	  the	  cornified	  envelope.	  This	  cornified	  envelope	  acts	   as	   a	   scaffold	   for	   the	   formation	   of	   an	   outer	   lipid	   envelope	   (Ishida-­‐Yamamoto	  1998;	  Candi,	  Schmidt	  et	  al.	  2005).	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Cell-­‐cell	  adhesion	  in	  the	  epidermis	  
	  There	   are	   several	   types	   of	   junctions	   found	   in	   the	   many	   layers	   of	   the	   epidermis	  (Figure	   I.2):	   tight	   junctions,	   adherens	   junctions/desmosomes	   and	   gap	   junctions	  (Candi,	  Schmidt	  et	  al.	  2005).	  Two	  types	  of	  cell	  junctions	  in	  the	  epidermis	  are	  found	  to	  be	  responsible	  mainly	  for	  cell	  cohesion:	  adherens	  junctions	  and	  desmosomes.	  
Adherens	   junctions	  mainly	   connect	   the	   actin	   filaments	   of	   adjacent	   cells	   together	  (Proksch,	  Brandner	  et	  al.	  2008).	  E-­‐cadherin,	  an	   important	  protein	   involved	   in	   the	  composition	   of	   adheren	   junctions,	   has	   shown	   reduced	   expression	   in	   spongiotic	  lesions,	   which	   is	   characteristic	   of	   AD	   lesions	   (Ohtani,	   Memezawa	   et	   al.	   2009).	  Desmosomes	  are	  involved	  in	  connecting	  the	  keratin	  filaments	  of	  neighboring	  cells,	  and	  will	  be	  talked	  about	  in	  more	  detail	  later.	  



















Gap	   junctions	  are	  mainly	   involved	   in	   intercellular	   transport	  of	  molecules,	  such	  as	  calcium	   and	  magnesium,	   between	   adjacent	   cells	   (Proksch,	   Brandner	   et	   al.	   2008),	  and	   are	   formed	   from	   the	   trans	  membranous	   protein	  molecules	   called	   connexins.	  Thus	   they	   are	   believed	   to	   have	   a	   major	   regulatory	   role	   in	   cell	   differentiation	  (Jensen	   and	   Proksch	   2009).	   Interestingly,	   AD	   patients	   have	   demonstrated	  increased	  expression	  of	  connexin-­‐26	  (De	  Benedetto,	  Yoshida	  et	  al.	  2012),	  which	  is	  associated	   with	   delayed	   skin	   barrier	   recovery	   in	   similar	   models	   	   (Djalilian,	  McGaughey	  et	  al.	  2006).	  	  
	  
I.III.II	  The	  epidermal	  barrier	  
The	  epidermal	  barrier	  is	  at	  the	  lower	  part	  of	  the	  SC,	  acting	  as	  a	  shield	  from	  various	  environmental	   influences	   (Cork,	  Danby	  et	  al.	  2008).	   It	   serves	  as	  a	  protector	   from	  chemical	  and	  physical	  forces	  (Proksch,	  Brandner	  et	  al.	  2008).	  It	  also	  functions	  as	  an	  antimicrobial	  barrier	  against	  infections	  (Elias,	  Hatano	  et	  al.	  2008).	  Furthermore,	  it	  regulates	  water	  diffusion	   from	   the	   skin	   into	   the	  environment,	  which	   is	  known	  as	  trans	  epidermal	  water	  loss	  (TEWL)(Elias	  2005).	  

















A.	  Filaggrin	  “	  reinforcing	  the	  brick”	  
	  Filaggrin	   can	   be	   considered	   one	   of	   the	   key	   elements	   in	   the	   formation	   of	   the	  cornified	  envelope.	  It	  was	  identified	  in	  1977,	  and	  was	  termed	  ‘filaggrin’	  for	  filament	  aggregating	   protein	   (Dale,	   Lonsdale-­‐Eccles	   et	   al.	   1980).	   It	   is	   derived	   from	  profilaggrin,	   which	   is	   a	   histidine	   rich	   polypeptide	   forming	   the	   keratohyalin	  granules	  located	  in	  the	  cytoplasm	  of	  cells	  in	  the	  stratum	  granulosum	  (O'Regan	  and	  Irvine	  2008).	  At	  the	  uppermost	  layer	  of	  the	  granular	  layer,	  profilaggrin	  is	  cleaved	  to	  form	  filaggrin	  in	  a	  process	  involving	  the	  protease	  caspase	  14	  (Kamata,	  Taniguchi	  et	  al.	  2009;	  Hoste,	  Kemperman	  et	  al.	  2011).	  
It	   then	  proceeds,	   in	   the	   lowermost	   two	   layers	  of	   the	  SC,	   to	   aggregate	   the	  keratin	  bundles,	   at	   the	   end	   of	  which	   it	   disintegrates	   into	   hydrophilic	   amino	   acids.	   These	  amino	   acids	   then	   become	   incorporated	   into	   what	   is	   called	   Natural	   Moisturizing	  Factor	  (NMF).	  NMF	  is	  important	  for	  water	  retention	  in	  the	  corneocytes,	  preserving	  moisture	   and	   giving	   the	   corneocytes	   flexibility	   (Cork,	   Danby	   et	   al.	   2009).	   It	   also	  aids	   in	   modulation	   of	   the	   SC	   pH,	   important	   for	   regulating	   protease	   activity	   and	  synthesis	  of	  the	  lipid	  lamellae	  (Rippke,	  Schreiner	  et	  al.	  2004;	  Hachem,	  Roelandt	  et	  al.	  2010).	  
Several	  structural	  defects	  of	  epidermal	  differentiation	  have	  been	  found	  in	  AD,	  the	  most	   prominent	   of	   them	   affecting	   filaggrin	   (Palmer,	   Irvine	   et	   al.	   2006).	   Filaggrin	  mutations	   were	   first	   identified	   in	   Icthyosis	   Vulgaris,	   a	   disease	   characterized	  primarily	  of	  dry,	  flaky	  skin	  and	  hyperlinearity	  of	  the	  palms	  and	  soles	  with	  seasonal	  variation	  (Dereure	  2007).	  	  
	  
28	  
Now,	   it	   is	   found	   in	   15-­‐50%	   of	   AD	   patients,	   and	   is	   associated	   with	   AD	   of	   higher	  severity	  (Irvine,	  McLean	  et	  al.	  2011).	  
Involucrin,	  in	  addition	  to	  being	  a	  structural	  component	  of	  the	  cornified	  envelope,	  is	  important	   for	   the	  attachment	  of	   lipids	   to	   the	  outer	   surface	  of	   the	   corneocyte	   cell	  membrane,	  enabling	  formation	  of	  the	  lipid	  envelope	  (Nemes,	  Marekov	  et	  al.	  1999).	  Research	   has	   also	   demonstrated	   reduced	   expression	   of	   involucrin	   in	  AD	   (Jensen,	  Folster-­‐Holst	  et	  al.	  2004).	  
	  
B.	  Lipid	  lamellae	  “The	  mortar”	  The	  lipid	  lamellae	  is	  an	  arrangement	  of	  lipids	  into	  lamellar	  sheets,	  which	  surround	  the	   corneocytes,	   filling	   the	  extracellular	   space	   (Feingold	  2007).	   It	   is	   composed	  of	  approximately	  50%	  ceramides,	  25%	  cholesterols	  and	  15%	   free	   fatty	  acids.	  These	  lipids	   are	   derived	   from	   both	   exogenous	   sources,	   and	   secretory	   granules	   in	   the	  keratinocytes	  coined	  lamellar	  bodies	  (Elias	  2008).	  	  Lamellar	  bodies	  are	   first	   seen	   in	   the	   stratum	  spinosum	  (Fartasch,	  Bassukas	  et	   al.	  1992).	  They	   then	  cluster	  and	   fuse	  with	   the	  apical	   cell	  membranes	   in	   the	   stratum	  granulosum	   and	   excrete	   their	   contents	   (Figure	   I.4),	   which	   are	   a	   mixture	   of	  phospholipids,	  sphingolipids	  (glucosylceramides,	  sphingomyelin)	  and	  cholesterols	  (Elias	   and	   Schmuth	   2009).	   Furthermore,	   they	   secrete	   various	   lipid	   processing	  enzymes,	   such	   as	   β-­‐glucocerebrosidase,	   acidic	   sphingomyelinase,	   and	   secretory	  phospholipase	  A2	  (Menon,	  Grayson	  et	  al.	  1988).	  These	  enzymes	  help	  metabolize	  the	  lipid	  precursors	  into	  the	  lipids	  that	  constitute	  the	  lipid	  lamellae	  (Fartasch	  2004).	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Research	  has	  shown	  reduced	  ceramide	  levels	  in	  the	  lipid	  lamellae	  of	  AD	  patients	  in	  comparison	  with	  healthy	  controls	  (Kawashima,	  Morita	  et	  al.	  1990;	  Imokawa,	  Abe	  et	  al.	  1991;	  Hara,	  Higuchi	  et	  al.	  2000).	  The	  reduction	  in	  ceramide	  levels	  was	  thought	  to	  be	  due	  to	  abnormal	  expression	  of	  enzymes,	  such	  as	  glucosylceramide	  deacylase	  (Ishibashi,	  Arikawa	  et	  al.	  2003),	  sphingomyelin	  acylase	  (Murata,	  Ogata	  et	  al.	  1996),	  and	  sphingomyelin	  deacylase	  (Hara,	  Higuchi	  et	  al.	  2000).	  
Studies	   have	   shown	   sphingomyelin	   deacylase,	   in	   particular,	   to	   have	   five	   times	  higher	   activity	   in	   AD	   lesional	   skin	   and	   approximately	   three	   times	   higher	   in	   non-­‐lesional	  AD	   skin	   in	   comparison	   to	  healthy	   controls.	   In	   addition,	   atypical	   forms	  of	  ceramides	  have	  also	  been	  found	  in	  AD	  (Bleck,	  Abeck	  et	  al.	  1999).	  
Furthermore,	  many	   aberrations	   have	   been	  discovered	   in	   lamellar	   bodies	   as	  well.	  Fartasch	  and	  colleagues	  found	  that	  in	  atopic	  skin,	   lamellar	  bodies	  have	  somewhat	  dysfunctional	   lipid	   extrusion	   (Fartasch,	   Bassukas	   et	   al.	   1992).	   In	   addition,	   there	  was	  a	  reduction	  in	  the	  number	  of	  lamellar	  bodies	  delivered	  and	  fused	  with	  the	  cell	  membrane	  in	  AD	  patients	  in	  comparison	  with	  controls.	  
	  
C.	  Corneodesmosomes	  “the	  iron	  rods”	  
	  Cornoedesmosomes,	  mentioned	  earlier,	  are	  specialized	  junctions	  found	  only	  at	  the	  SC	   level	   (Serre,	  Mils	   et	   al.	   1991).	   They	   are	   formed	   from	  desmosomes,	  which	   are	  junctions	   composed	   of	   proteins	   such	   as	   desmoglein-­‐1,	   desmocollin,	   and	  plakoglobulin	  and	  plakophilin	  (Candi,	  Schmidt	  et	  al.	  2005).	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These	   then	   become	   reinforced	   with	   a	   protein	   expressed	   in	   the	   upper	   granular	  layers	   of	   the	   epidermis,	   corneodesmosin	   (Serre,	  Mils	   et	   al.	   1991).	   Together,	   they	  form	   one	   of	   the	   main	   structures	   responsible	   for	   corneocyte	   cohesion,	   the	  corneodesmosome.	  
Proteases,	  such	  as	  kallikriens	  (KLK),	  are	  also	  secreted	  by	  lamellar	  bodies	  and	  act	  by	  cleaving	  the	  corneodesmosomes	  (Cork,	  Danby	  et	  al.	  2008).	  This	  leads	  to	  separation	  of	   the	   corneocytes,	   and	   shedding	   (Cork,	   Danby	   et	   al.	   2008).	   	   Other	   corneocytes,	  advancing	   from	  below,	   already	  differentiated,	   replace	   these	   cells	   (Egelrud	  2000).	  Hence	   the	   stratum	  corneum	   is	   continually	   renewed	  but	  maintained	  at	   a	   constant	  thickness	  in	  a	  process	  called	  desquamation	  (Egelrud	  2000).	  







Protease	  inhibitors	  are	  equally	  important	  in	  controlling	  the	  desquamation	  process	  (Egelrud	  2000).	   In	  disorders	  such	  as	  Netherton	  syndrome,	  which	   is	  characterized	  by	  generalized	  scaly	  erythroderma	  and	  atopic	  manifestations	  (Bitoun,	  Chavanas	  et	  al.	   2002),	   mutations	   have	   been	   found	   in	   the	   serine	   protease	   inhibitor	   Kazal-­‐5	  
(SPINK-­‐5)	  gene,	  encoding	  for	  the	  protease	  inhibitor	  SPINK-­‐5,	  previously	  known	  as	  
Lympho-­‐epithelial	   Kazal-­‐type	   5	   serine	   protease	   inhibitor	   (LEKTI)	   (Chavanas,	  Bodemer	  et	  al.	  2000).	  	  











Figure	  I.	  5:	  Defects	  identified	  in	  the	  skin	  barrier.	  The	   structural	   protien,	   filaggrin,	   is	   abnormal	   due	   to	  mutations	   in	   the	   filaggrin	   encoding	  gene	   (Palmer,	   Irvine	   et	   al.	   2006).	   This	   leads	   to	   fragile	   corneocytes	   and	   decreased	   NMF.	  Protease	  inhibitors	  have	  also	  been	  found	  to	  have	  reduced	  activity	  (Vasilopoulos,	  Cork	  et	  al.	  2004);	  there	  also	  are	  abnormalities	  in	  protease	  activity	  (Saaf,	  Tengvall-­‐Linder	  et	  al.	  2008).	  Antimicrobial	  peptides	  (AMP)	  and	  ceramide	  levels	  have	  been	  found	  to	  be	  abnormal	  in	  AD.	  All	  these	  can	  lead	  to	  breakdown	  of	  the	  epidermal	  barrier,	  and	  the	  manifestation	  of	  AD.	  	  	  	  	  	  
impaired	  skin	  barrier	  fnc.	  Filaggrin	  
decreased	  protease	  inhibitor	  function	  e.g.	  SPINK	  5	  
increased	  protease	  activity	  e.g.	  kallikrein7	   abnormal	  ceramide	  levels	  in	  the	  lipid	  lamallae	  
dysregulated	  AMP	  levels	  (LL-­‐37)	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Component	   Function	   Defect	   associated	   with	  
AD	  	  Structural	  components	  
- Filaggrin	  
- Involucrin	  
	  Stability,	  NMF,	  pH	  balance	   	  Decreased	  expression	  (Palmer	  et	  al,	  2006)	  (Jensen	  et	  al,	  2004)	  Cell-­‐cell	  adhesion	  	  
- Tight	  junctions	  (claudins)	  	  
- Gap	  junctions	  (connexins)	  	  	  
- Corneo-­‐desmosomes	  
	  	   Stability,	  intercellular	  regulation	  	  
	  	  Decreased	   expression	   of	  claudin	  (De	  Benedetto	  et	  al,	  2011)	  Increased	   expression	   of	  connexin26	  (De	  Benedetto	  et	  al,	  2012)	  	  Decreased	   expression	   of	  desmoglein-­‐1	  (De	  Benedetto	  et	  al,	  2008)	  	  Lipids	  	  
- Lamellar	  bodies	  
- Sphingolipids	  (ceramides)	  
	  	   Water	  repellence,	  Hydration,	  pH	  balance	  
	  Dysfunctional	  lipid	  extrusion	  (Fartasch	  et	  al,	  1992)	  Decreased	  ceramide	  levels	  (Hara	  et	  al,	  2000)	  Regulatory	  enzymes	  	  
- Proteases	  (KLKs)	  	  	  	  	  	  
- Protease	  inhibitors	  
	  	   Regulation	  of	  the	  desquamation	  process	  
	  	  Overexpression	  of	  proteases	  (Saafi	  et	  al,	  2008)	  	  Increased	  activity	  (Vasilopoulos	  et	  al,	  2004)	  	  	  Reduced	  expression	  (Kato	  et	  al,	  2003)	  	  
Table	   1.	   The	   different	   components	   involved	   in	   epidermal	   differentiation,	   and	   the	  




I.III.III	  The	  antimicrobial	  barrier	  
One	  of	  the	  main	  functions	  of	  the	  epidermal	  barrier	  is	  antimicrobial	  defense.	  This	  is	  achieved	  by	  both	  maintenance	  of	  skin	  surface	  pH	  (Korting,	  Lukacs	  et	  al.	  1992),	  and	  through	  expression	  of	  antimicrobial	  peptides	  (AMP)	  (Lai	  and	  Gallo	  2009).	  
	  
A.	  Skin	  Surface	  pH:	  
	  It	   was	   Schade	   and	   Marchionini	   whom	   first	   described	   the	   skin	   surface	   as	   being	  acidic	   and	   most	   favorable	   for	   skin	   barrier	   function	   (1928).	   Firstly,	   proteases	  function	   under	   neutral	   pH	   (7.0).	   As	   the	   pH	  decreases,	   so	   does	   the	   activity	   of	   the	  proteases	   (Rippke,	   Schreiner	   et	   al.	   2004),	   thereby	  maintaining	   stratum	   corneum	  cohesion	   (Figure	   I.6).	   This	   finding	   was	   demonstrated	   on	   hairless	   mice	   (Hachem	  2003;	   Fluhr,	   Mao-­‐Qiang	   et	   al.	   2004).	   	   Secondly,	   low	   pH	   aids	   the	   formation	   and	  organization	  of	  the	  lipid	  lamellae	  (Bouwstra,	  Gooris	  et	  al.	  1998;	  Pilgram,	  Vissers	  et	  al.	  2001).	  This	  is	  because	  the	  afore-­‐mentioned	  lipid	  processing	  enzymes	  have	  acidic	  optimum	  (Elias,	  Williams	  et	  al.	  2002).	  	  Finally,	  an	  acidic	  environment	  is	  important	  for	  discouraging	  colonization	  of	  pathogenic	  bacteria,	  such	  as	  Staphylococcus	  aureus	  (S.	  aureus)	  and	  propionibacteria	  (Korting,	  Lukacs	  et	  al.	  1992).	  
As	  mentioned	  previously,	   filaggrin	  mutations	  can	  result	   in	  disruption	  of	   the	  NMF,	  resulting	   in	   increased	  pH.	   In	  addition,	  disturbed	   lipid	  processing	   can	  also	   lead	   to	  elevated	  pH.	  Protease	  activityis	  elevated	  as	  a	  consequence,	   leading	   to	  cleavage	  of	  the	  cornoedesmosomes	  (Rippke,	  Schreiner	  et	  al.	  2002).	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This	   in	   turn	   results	   in	   disintegration	   of	   the	   corneocytes,	   and	   barrier	   breakdown	  (Rippke,	   Schreiner	   et	   al.	   2002).	   Elevated	   pH	   can	   also	   cause	   swelling	   of	   the	  corneocytes	  and	  modification	  of	  the	  lipid	  structure	  (Bouwstra,	  Gooris	  et	  al.	  1998).	  A	  recent	  study	  demonstrated	  a	  clear	  association	  between	  AD	  patients	  with	  filaggrin	  mutations	  and	  elevation	  of	  skin	  surface	  pH	  (Jungersted,	  Hogh	  et	  al.	  2010)	  


















decreased	  skin	  pH	  
discourages	  harmful	  bacteria	   prevents	  skin	  infection	  
formation	  of	  lipid	  lamella	  
decreased	  protease	  (P)	  activity	  
increased	  protease	  inhibitor(PI)	  activity	  
maintain	  skin	  thickness	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B.	  Antimicrobial	  peptides	  







	  Cathelicidins	   are	  AMPs	   characterized	   by	   an	  N-­‐terminal	   cathelin	   domain	   and	   a	   C-­‐terminus	   with	   antimicrobial	   activity	   (Bals	   and	  Wilson	   2003).	   	   In	   the	   epidermis,	  they	   are	   stored	   as	   inactive	   precursors	   (h-­‐CAP18)	   within	   the	   lamellar	   bodies	   in	  keratinocytes	   (Braff,	   Di	   Nardo	   et	   al.	   2005).	   They	   are	   then	   extruded	   at	   the	   upper	  level	   of	   the	   stratum	   granulosum,	   and	   liberated	   as	   the	   active	   form	   LL-­‐37	   by	  extracellular	  cleavage	  with	  KLK	  5	  and	  7	  (Morizane,	  Yamasaki	  et	  al.	  2010).	  
Although	  there	  are	  several	  different	  types	  of	  cathelicidins	  identified	  in	  bovine	  and	  porcine	   tissue	   (Zanetti,	   Gennaro	   et	   al.	   1995),	   only	   one	   type	   (h-­‐CAP18)	   has	   been	  identified	  so	  far	  in	  humans	  (Cowland,	  Johnsen	  et	  al.	  1995).	  LL-­‐37,	  specifically,	  has	  been	   found	   in	  abundance	   in	  several	   tissues	  of	   the	  body	  such	  as	   lung	  airway	   fluid	  (Agerberth,	  Grunewald	  et	   al.	   1999),	   plasma	   (Sorensen,	  Cowland	  et	   al.	   1997),	   and	  the	  epithelial	  cells	  of	  the	  epididymis	  (Malm,	  Sorensen	  et	  al.	  2000).	  


















Gram-­‐positive	  bacteria	  are	  also	  susceptible,	  however	  the	  mechanisms	  have	  yet	   to	  be	  understood	  (Nelson,	  Hultenby	  et	  al.	  2009).	  LL-­‐37	  has	  also	  been	  shown	  to	  have	  the	  capability	  to	  bind	  and	  inactivate	  bacterial	  endotoxin	  (Hirata,	  Kirikae	  et	  al.	  1998;	  Kirikae,	  Hirata	  et	  al.	  1998).	  
Despite	   this,	  many	  bacteria	  have	  developed	  resistance	  against	   the	  effects	  of	  AMP.	  
Shigella	   species	   have	   been	   shown	   to	   release	   plasmid	   DNA	   which	   inhibits	   the	  expression	   of	   LL-­‐37	   (Lai	   and	   Gallo	   2009).	   S.	   aureus	   can	   release	   proteases	   to	  inactivate	  LL-­‐37	  (Sieprawska-­‐Lupa,	  Mydel	  et	  al.	  2004),	  as	  well	  as	  modulate	  the	  LPS	  surface	   membrane,	   reducing	   their	   recognizing	   properties	   (Peschel	   and	   Collins	  2001).	  
LL-­‐37	  has	  also	  shown	  significant	  anti	  viral	  activity	  (Figure	  I.8).	  In	  vivo	  and	  In	  vitro	  studies	   show	   inhibited	   replication	   of	   HSV	   (Howell,	   Wollenberg	   et	   al.	   2006),	   the	  Influenza	  virus	  (Barlow,	  Svoboda	  et	  al.	  2011),	  the	  Vaccinia	  virus	  (Howell,	  Jones	  et	  al.	  2004)	  and	  HIV	  (Wang,	  Watson	  et	  al.	  2008)	  when	  exposed	  to	  cathelicidins.	  LL-­‐37	  also	   displays	   anti-­‐fungal	   activity	   (Lopez-­‐Garcia,	   Lee	   et	   al.	   2005;	   Tsai,	   Yang	   et	   al.	  2011).	  

















In	  addition,	  LL-­‐37	  was	  found	  to	  inhibit	  maturation	  of	  dendritic	  cells	  (DC)	  (Kandler,	  Shaykhiev	   et	   al.	   2006),	   and	   the	   release	   of	   TNFα	   from	   monocytes	   (Mookherjee,	  Brown	   et	   al.	   2006).	   Therefore	   it	   is	   possible	   that	   it	   has	   a	   regulatory	   effect	   on	  inflammatory	  responses.	  
Furthermore,	   LL-­‐37	   appears	   to	   be	   important	   for	   wound	   repair.	   It	   has	   shown	   to	  promote	  keratinocyte	  migration	  to	  aid	  re-­‐	  epithelialization	  (Tokumaru,	  Sayama	  et	  al.	   2005). It	   also	   apparently	   stimulates	   endothelial	   cell	   proliferation	   to	   promote	  angiogenesis	   (Koczulla,	   von	   Degenfeld	   et	   al.	   2003).	   	   It	   directly	   acts	   on	   dermal	  fibroblasts,	   inhibiting	   collagen	   release	  and	   fibrosis	  of	  wounds,	  promoting	  healthy	  wound	  development	  (Park,	  Cho	  et	  al.	  2008).	  
	  
Cathelicidin	  levels	  in	  AD	  patients	  





Patients	   were	   stratified	   into	   AD,	   and	   ADEH.	   Ten	   AD	   patients	   were	   biopsied,	   in	  addition	   to	   ten	   ADEH	   patients.	   It	   was	   found	   that	   not	   only	   are	   LL-­‐37	   levels	  decreased	   in	   AD	   patients	   with	   HSV,	   but	   that	   their	   levels	   were	   significantly	   less	  (p<0.05)	  than	  those	  in	  uncomplicated	  AD	  patients.	  
I.IV.	  Pathophysiology	  of	  AD	  	  AD	  is	  identified	  as	  being	  the	  first	  step	  in	  the	  ‘atopic	  march’,	  progressing	  to	  asthma	  and	  allergic	  rhinitis	  (Cantani	  1999).	   	  This	  atopic	  march	  occurs	  early;	  over	  50%	  of	  AD	  children	  will	  develop	  asthma	  or	  allergies	  before	  the	  age	  of	  three	  (Boguniewicz	  and	  Leung	  2011).This	  is	  due	  to	  a	  primary	  skin	  barrier	  defect,	  accompanied	  with	  an	  adaptive	  immunity	  Th1-­‐Th2	  paradigm	  (Zheng,	  Yu	  et	  al.	  2011).	  

























Monocytes	  in	  AD	  also	  exhibit	  the	  FcεRI	  receptor,	  as	  well	  as	  an	  increased	  production	  of	  prostaglandin	  E2	  (Bolognia,	  Jorizzo	  et	  al.	  2003).	  This	  leads	  to	  increased	  secretion	  of	   IL-­‐10,	   inhibiting	  Th1	   cell	   activity	   and	  encouraging	  a	  Th2	  predominant	   infiltrate	  composed	   of	   IL-­‐4,	   IL-­‐5,	   and	   IL-­‐13.	   This	   encourages	   further	   switching	   to	   the	   IgE	  antibody	  class	  (Galli,	  Tsai	  et	  al.	  2008).	  
Interestingly,	   IL-­‐4	   and	   IL-­‐13	   both	   have	   shown	   to	   down	   regulate	   expression	   of	  filaggrin	  (Howell,	  Kim	  et	  al.	  2007),	  loricrin	  and	  involucrin	  (Kim,	  Leung	  et	  al.	  2008),	  thereby	   leading	   to	   reduced	   cornified	   envelope	   formation	   and	   decreased	   skin	  barrier	  integrity.	  
Consequently,	   IgE	   diffuses	   systemically	   via	   blood	   and	   lymphatics,	   creating	   a	   Th2	  predominant	  immune	  system.	  Subsequent	  exposure	  to	  allergens	  leads	  to	  mast	  cell	  degranulation	  and	  release	  of	  histamine	  and	  leukotrienes	  (Galli,	  Tsai	  et	  al.	  2008).	  
The	   persistent	   inflammation	   seen	   in	   AD	   is	   due	   to	   the	   ongoing	   inflammation	  associated	  with	   tissue	  damage	   (Dimeloe,	  Nanzer	   et	   al.	   2010).	   In	   chronic	   or	  more	  severe	   AD,	   Th1	   cells	   are	   also	   thought	   to	   contribute	   to	   ongoing	   inflammation,	  possibly	  through	  ongoing	  secretion	  of	  the	  immunomodulatory	  cytokine	  interferon	  γ	  (IFNγ)	  (Grewe,	  Bruijnzeel-­‐Koomen	  et	  al.	  1998;	  Dokmeci	  and	  Herrick	  2008)	  




Although	   some	   studies	   have	   reported	   diminished	   IL-­‐17	   levels	   in	   AD	   patients	  (Hayashida,	   Uchi	   et	   al.	   2011),	   others	   have	   found	   high	   levels	   (Toda,	   Leung	   et	   al.	  2003)	  and	  some	  have	   found	  normal	   levels	   (Nograles,	  Suarez-­‐Farinas	  et	  al.	  2010).	  Some	  research	  has	  suggested	  that	  Th2	  counteracts	  Th17,	  preventing	  AMP	  induction	  (Eyerich,	  Pennino	  et	  al.	  2009).	  
	  
T	  regulatory	  cells	  
In	  healthy	  individuals,	  regulatory	  T	  cells	  (TRegs)	  aid	  in	  the	  down	  regulation	  of	  the	  inflammatory	   response.	   They	   can	   be	   classified	   into	   two	   subgroups:	   naturally	  occurring	  TRegs	  (nTRegs)	  produced	  in	  the	  thymus,	  and	  induced	  TRegs	  (iTRegs),	  in	  response	   to	   infection	   and	   cancer	   (McGuirk,	   Higgins	   et	   al.	   2010).	   The	   nTRegs	  express	   forkhead-­‐winged	   helix	   transcription	   factor,	   forkhead	   box	   P3	   (Fox	   P3),	  which	  are	  apparently	  important	  for	  TReg	  cell	  function	  (Sakaguchi	  2000).	  Not	  only	  do	  nTRegs	  release	  inhibitory	  cytokines,	  but	  they	  also	  directly	  block	  DC	  maturation,	  and	   as	   a	   consequence	   suppress	   their	   ability	   to	   activate	   T	   effector	   cells	   (Onishi,	  Fehervari	  et	  al.	  2008).	  	  





IL-­‐10	   has	   shown	  many	   anti-­‐allergic	   properties,	   such	   as	  mast	   cell	   and	   eosinophil,	  inhibition. It	   also	   acts	   on	   B	   cells,	   stimulating	   a	   switch	   to	   IgG4	   production,	   an	  antibody	  that	  was	  found	  to	  inhibit	  IgE	  mediated	  histamine	  release	  (Till,	  Francis	  et	  al.	   2004).	   TGF-­‐β	   also	   acts	   by	   inhibiting	   Th1	   and	   Th2	   inflammation	   (Veldhoen,	  Uyttenhove	  et	  al.	  2008).	  
In	   AD,	   TReg	   functions	   have	   been	   found	   to	   be	   impaired	   (Hawrylowicz	   2005).	   In	  addition,	  studies	  have	  found	  decreased	   levels	  of	  TGF-­‐β	  and	  Fox	  P3+	  TRegs	  cells	   in	  the	  lung	  cells	  of	  asthmatic	  patients	  when	  compared	  with	  healthy	  controls	  (Luo,	  Liu	  et	  al.	  2006).	  	  
This	   is	   especially	   evident	   in	   the	   disorder	   called	   immune	   dysregulation	  polyendocrinopathy	  X-­‐linked	  (IPEX),	  which	  is	  characterized	  by	  autoimmunity	  and	  marked	  atopy	  in	  the	  form	  of	  AD,	  food	  allergies	  and	  high	  IgE	  levels	  (Li,	  Samanta	  et	  al.	  2007).	  Asthma	  patients	  were	  found	  to	  have	  lesser	  levels	  than	  healthy	  controls	  of	  TRegs	  in	  broncho	  alveolar	  lavage	  (Hartl,	  Koller	  et	  al.	  2007).	  The	  peripheral	  blood	  of	  people	  suffering	  from	  hay	  fever	  were	  also	  found	  to	  contain	  decreased	  levels	  TRegs	  in	   comparison	  with	   controls	   (Ling,	   Smith	   et	   al.	   2004).	   Some	   have	   also	   identified	  specific	  FoxP3	  gene	  polymorphisms	  associated	  with	  allergic	  rhinitis	  (Zhang,	  Zhang	  et	  al.	  2009).	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I.V.	  Vitamin	  D	  and	  AD	  
The	   role	   of	   vitamin	   D	   (VD)	   in	   bone	   mineralization	   has	   been	   recognized	   and	  confirmed	  for	  several	  decades	  (Anderson,	  Turner	  et	  al.	  2012).	  	  Recently,	  however,	  the	   extra	   skeletal	   importance	  of	  VD	  has	   increasingly	  become	   recognized	   (Bartley	  2010).	   Recent	   studies	   have	   associated	   VD	   deficiency	   with	   an	   increased	   risk	   of	  malignancy	   (Pilz,	  Tomaschitz	  et	  al.	  2009),	   cardiovascular	  disease	   (Shirts,	  Howard	  et	   al.	   2012),	   and	   autoimmune	   disorders	   (Andreoli,	   Piantoni	   et	   al.	   2012).	   VD	   is	  involved	  in	  various	  processes	  in	  the	  body,	  and	  some	  have	  even	  argued	  its	  essential	  role	  in	  evolution	  (Bikle	  2011).	  In	  addition,	   it	  appears	  to	  have	  significant	  immuno-­‐	  modulating	   effects	   in	   both	   the	   innate	   and	   adaptive	   immune	   systems	   (Hewison	  2010;	  Peelen,	  Knippenberg	  et	  al.	  2011).	  







I.V.I.	  VD	  Sources	  
VD	  is	  acquired	  from	  two	  major	  sources:	  diet	  and	  sunlight,	  which	  is	  responsible	  for	  more	  than	  90	  %	  of	  an	  individuals	  supply	  (Box	  2)	  (Pearce	  and	  Cheetham	  2010).	  Fair	  skinned	  people	  require	  20-­‐30	  minutes	  of	   sunlight	   three	   times	  a	  week	   in	  order	   to	  achieve	   optimum	   VD	   levels	   (Pearce	   and	   Cheetham	   2010).	   The	   elderly,	   and	  individuals	   with	   darker	   skin	   will	   need	   approximately	   twice	   as	   much	   to	   achieve	  healthy	  levels	  (Working	  Group	  of	  the,	  New	  Zealand	  et	  al.	  2005).	  Two	  main	  forms	  of	  VD	  exist:	  VD3	  (cholecalciferol),	  which	  is	  formed	  in	  the	  skin	  and	  can	  also	  be	  obtained	  through	  the	  diet	  from	  animal	  sources,	  and	  VD2	  (ergocalciferol),	  obtained	  from	  fungi	  (Baeke,	  Takiishi	  et	  al.	  2010).	  
	  
	  
Sources	  of	  VD	  1. Ultraviolet	  light	  2. Oily	   fish:	   mackerel,	   salmon,	   sardines,	   tuna	   (smoked=160	   IU;	  raw=1600IU/100	  gm).	  3. Fish	  oils:	  cod	  liver	  oil	  4. Mushrooms	  (very	  minimal	  amounts).	  5. Eggs:	  specifically	  the	  egg	  yolk	  (20	  IU	  per	  yolk).	  6. Fortified	  milk	  and	  fortified	  cereals	  (160	  IU-­‐320/100gm).	  
	  
Box	  2.	  	  Sources	  of	  VD.	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I.V.II.	  Clinical	  manifestation	  of	  VD	  deficiency	  
VD	   deficiency	   is	   generally	   thought	   to	   present	   as	   skeletal	   abnormalities,	   with	   an	  increase	   in	   fractures,	   and	   in	   severe	   cases,	   bowing	   of	   legs	   and	   knock	   knees,	  manifesting	   as	   rickets	   (Mughal	   2011).	   It	   can,	   however,	   present	   a	   subtler	   picture,	  with	  increased	  irritability,	  a	  history	  of	  multiple	  infections	  and	  poor	  growth	  (Beck-­‐Nielsen,	  Jensen	  et	  al.	  2009).	  	  
In	   adults,	   VD	   deficiency	   can	   manifest	   has	   general	   pain	   and	   muscle	   weakness	  (Pearce	   and	   Cheetham	   2010).	   Research	   has	   also	   linked	   VD	   deficiency	   to	   chronic	  low	  back	  pain	  (Lewis	  2005;	  Atherton,	  Berry	  et	  al.	  2009;	  Straube,	  Moore	  et	  al.	  2009).	  
	  
I.V.III.	  VD	  and	  the	  Skin	  barrier	  



































Increased	   calcium	   levels	   along	   the	   gradient	   also	   induce	   keratinocytes	   to	   switch	  from	   producing	   Keratins	   5	   and	   14	   to	   K1	   and	   K10	   (Yuspa,	   Kilkenny	   et	   al.	   1989).	  This,	   shortly	   after,	   is	   followed	   by	   an	   increased	   production	   of	   profilaggrin,	  involucrin	  and	  loricrin,	  all	  of	  which	  are	  essential	  for	  cornified	  envelope	  formation	  (Hohl,	   Lichti	   et	   al.	   1991),	   and	   is	   evident	  within	   two	  days	  of	   extracellular	   calcium	  increase	  (Hennings,	  Steinert	  et	  al.	  1981).	  	  VDR,	   specifically,	   is	   reportedly	   essential	   in	   inducing	   expression	   of	   the	   genes	   that	  encode	  the	  protiens	  required	  for	  gap	  junctions	  (Clairmont,	  Tessmann	  et	  al.	  1996).	  adherens	  junctions	  (Gniadecki,	  Gajkowska	  et	  al.	  1997;	  Lopes,	  Carvalho	  et	  al.	  2012)	  and	   tight	   junctions	   (Chirayath	  1998;	  Kong,	  Zhang	  et	  al.	  2008).	   	  Furthermore,	  VD3	  has	   also	   been	   shown	   to	   directly	   induce	   expression	   of	   both	   involucrin	   and	  transglutaminases	  via	  VDR	  (Su,	  Bikle	  et	  al.	  1994;	  Bikle,	  Oda	  et	  al.	  2004).	  	  
In	  vivo	  studies	  in	  mice	  with	  mutated	  VDR	  or	  1α	  hydroxylase	  have	  shown	  decreased	  involucrin	   and	   profilaggrin	   in	   addition	   to	   loss	   of	   keratohyalin	   granules	   (Xie,	  Komuves	   et	   al.	   2002).	   The	   1α	   hydroxylase	   null	   mice	   also	   demonstrated	   an	  abnormal	   calcium	   gradient	   in	   the	   epidermis,	   and	   delayed	   skin	   barrier	   recovery	  (Bikle,	  Chang	  et	  al.	  2004).	  	  In	  addition,	  the	  VDR	  has	  been	  shown	  to	  affect	  sphingolipid	  production,	  specific	  to	  the	   epidermis	   (Oda,	   Uchida	   et	   al.	   2009).	   Silencing	   of	   VDR	   in	   mice	   resulted	   in	  decreased	  sphingolipid	  production,	  decreased	  expression	  of	  the	  enzyme	  ceramide	  glucosyl	  transferase,	  and	  defects	  in	  lamellar	  body	  formation.	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The	  effect	  of	  VD3	  on	  LL-­‐37	  
	  Of	  particular	  interest	  is	  the	  effect	  of	  VD3	  on	  the	  expression	  of	  cathelicidins	  (Beard,	  Bearden	   et	   al.	   2011).	   Interestingly	   enough,	   only	   the	   gene	   encoding	   for	   human	  cathelicidin,	  CAMP	   (cathelicidin	  anti	  microbial	  peptide),	  contains	  the	  VD	  response	  element	   (VDRE)	   (Gombart,	   Saito	   et	   al.	   2009).	   An	   important	   study	   revealed	   the	  presence	   of	   VDRE	   mediated	   cathelicidin	   production	   in	   human	   keratinocytes,	  monocytes	   and	   neutrophils	   (Wang,	   Nestel	   et	   al.	   2004).	   These	   cells	  were	   directly	  stimulated	   with	   VD3,	   and	   were	   found	   to	   increase	   cathelicidin	   secretion	   via	  induction	  of	  CAMP	  gene	  expression.	  	  Yuk	   et	   al	   found	   that	   VD3	   induces	   autophagy	   of	   monocytes	   and	   destruction	   of	  




I.V.IV	  VD	  and	  the	  Innate	  Immune	  system	  



































This	   was	   explained	   to	   be	   a	   negative	   feedback	   mechanism,	   preventing	  disproportionate	   TLR	   activation	   and	   inflammation	   at	   the	   late	   stages	   of	   infection	  (Baeke,	  Takiishi	  et	  al.	  2010).	  	  Antigen	  presenting	  DCs	   are	   affected	  by	  VD3	   as	  well	   (Baeke,	   Takiishi	   et	   al.	   2010).	  These	  cells	  essentially	  link	  the	  innate	  and	  adaptive	  immune	  systems	  together.	  DCs	  capture,	  process	  and	  present	  antigens	  to	  the	  T	  lymphocytes	  (Baeke,	  Takiishi	  et	  al.	  2010).	  They	  also	  have	  been	  found	  to	  express	  VDR,	  and	  their	  antigen	  presentation	  seems	  to	  be	  inhibited	  when	  adding	  VD3	  in	  vitro	  (Penna	  and	  Adorini	  2000).	  This	  is	  thought	  to	  prevent	  over	  stimulation	  of	  T	  cells;	  a	  conclusion	  supported	  by	  the	  lower	  graft	   rejection	  rate	  of	  mice	   treated	  with	  VD3	   (Adorini,	  Penna	  et	  al.	  2001;	  Gregori,	  Casorati	  et	  al.	  2001).	  	  
I.V.V.	  VD	  and	  the	  Adaptive	  Immune	  System	  
	  Historically,	  there	  was	  controversy	  surrounding	  VD	  and	  its	  effect	  in	  allergy,	  due	  to	  the	  negative	  effects	  found	  in	  mice	  (Li,	  Hener	  et	  al.	  2006).	  It	  has	  increasingly	  become	  evident,	   however,	   that	   VD	   has	   a	   positive	   outcome	   on	  AD	   (Sidbury,	   Sullivan	   et	   al.	  2008;	  Javanbakht,	  Keshavarz	  et	  al.	  2011;	  Peroni,	  Piacentini	  et	  al.	  2011).	  	  The	  role	  of	  VD3	   in	  the	  adaptive	  immune	  system	  is	  still	  under	  scrutiny.	  It	  has	  been	  shown	  to	  inhibit	  production	  of	  IFNγ,	   the	  principal	  Th1	  cytokine	  (Mahon,	  Wittke	  et	  al.	   2003),	   however	   it	   has	   been	   shown	   both	   to	   promote	   (Boonstra,	   Barrat	   et	   al.	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2001)	   	   and	   inhibit	   (Staeva-­‐Vieira	   and	  Freedman	  2002)	   expression	  of	  Th2	   cells.	   It	  could	  be	  that	  different	  concentrations	  of	  VD3	  could	  explain	  the	  differing	  effects	  on	  Th2	   differentiation.	   High	   concentrations	   of	   VD3	   have	   been	   found	   to	   induce	   Th2	  secretory	   cytokines	   in	   vitro,	   whereas	   low	   concentrations	   were	   suppressive	  (Dimeloe,	  Nanzer	  et	  al.	  2010).	  Hyponnen	  et	  al	  (2009)	  in	  a	  recent	  study	  found	  that	  excessively	   high	   (<135nmol/L)	   and	   very	   low	   (<25nmol/)	   VD	   levels	   were	  associated	  with	  high	  serum	  IgE	  levels	  in	  British	  adults,	  which	  is	  consistent	  with	  the	  above	  in	  vitro	  results.	  	  On	   Th17,	   considered	   to	   induce	   AMP	   production	   as	  mentioned	   previously,	   studies	  have	  also	  produced	  contradicting	  results.	  VD3	  has	  been	  shown	  to	  increase	  (Peelen,	  Knippenberg	  et	  al.	  2011)	  and	  decrease	  IL-­‐17	  (Palmer,	  Lee	  et	  al.	  2011).	  Therefore,	  more	  research	  is	  needed	  in	  this	  area.	  	  Again,	   there	   have	   been	   conflicting	   results	   with	   regards	   to	   VD3	   effects	   on	   the	  inflammatory	   regulators,	   the	   TReg	   cells,	   another	   population	   found	   to	   have	  impaired	   function	   in	   AD	   (Hawrylowicz	   2005).	   In	   mice,	   VD3	   was	   found	   to	   either	  reduce	  TReg	  levels	  (Chang,	  Cha	  et	  al.	  2010)	  or	  have	  no	  effect	  (Mayne,	  Spanier	  et	  al.	  2011).	  Human	  studies	  on	  the	  other	  hand	  found	  that	  VD3	  stimulates	  the	  production	  of	   IL-­‐10	   producing	   TReg	   cells,	   important	   for	   Th2	   response	   regulation	   (Xystrakis,	  Kusumakar	   et	   al.	   2006).	   This	   is	   also	   the	   effect	   of	   corticosteroids,	   which	   are	  extensively	  used	  in	  the	  treatment	  of	  atopy	  (Dimeloe,	  Nanzer	  et	  al.	  2010).	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A	   positive	   correlation	   has	   been	   found	   between	   VD3	   and	   FoxP3+	   TReg	   levels	  (Hamzaoui,	   Dhifallah	   et	   al.	   2010)	   and	   VD3	   levels	   and	   FoxP3+	   TReg	   function	  (Smolders,	   Thewissen	   et	   al.	   2009)	   in	   patients	   with	   autoimmune	   disorders.	  Therefore	  VD3	  seems	  to	  have	  positive	  effects	  on	  TRegs.	  	  
I.V.	  	  Aims	  of	  this	  study	  	  	  Previous	  studies	  have	  found	  reduced	  levels	  of	  the	  human	  cathelicidin	  LL-­‐37	  in	  AD	  and	  ADEH	  patients	  in	  skin	  biopsies	  from	  lesional	  skin	  (Mallbris,	  Carlen	  et	  al.	  2009;	  Hata,	   Kotol	   et	   al.	   2010).	   VD	   supplementation	   was	   also	   reported	   to	   increase	  expression	  of	   LL-­‐37	   (Frohm,	  Agerberth	   et	   al.	   1997;	  Hata,	   Jackson	   et	   al.	   2008).	   In	  addition,	  small,	  randomized	  controlled	  trials	  (RCTs)	  have	  found	  an	  improvement	  in	  the	   severity	   of	   AD	   with	   VD	   supplementation	   (Sidbury,	   Sullivan	   et	   al.	   2008;	  Javanbakht,	  Keshavarz	  et	  al.	  2011;	  Amestejani,	  Salehi	  et	  al.	  2012).	  	  Therefore,	  to	  date,	  there	  have	  been	  twelve	  studies	  examining	  the	  effect	  of	  VD	  status	  on	  AD	  severity	  (Giannetti,	  Ricci	  et	  al.	  2011;	  Peroni,	  Piacentini	  et	  al.	  2011;	  Shim,	  Kim	  et	   al.	   2012),	   the	   relationship	   between	   VD	   and	   LL-­‐37	   (Howell,	   Wollenberg	   et	   al.	  2006;	  Leung,	  Wollenberg	  et	  al.	  2006;	  Mallbris,	  Carlen	  et	  al.	  2009)	  and	  the	  effect	  of	  VD	  supplementation	  on	  both	  AD	  and	  LL-­‐37	  levels	  (Hata,	  Jackson	  et	  al.	  2008;	  Hata,	  Kotol	   et	   al.	   2008;	   Sidbury,	   Sullivan	   et	   al.	   2008;	   Stahle,	   Mallbris	   et	   al.	   2008;	  Javanbakht,	  Keshavarz	  et	  al.	  2011;	  Amestejani,	  Salehi	  et	  al.	  2012).	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Together,	  all	  previous	  research	  suggests	  that	  VD	  supplementation	  is	  of	  benefit	  in	  AD;	  this	  is	  likely	  to	  be	  greater	  in	  ADEH,	  and	  altered	  LL-­‐37	  expression	  is	  a	  possible	  mechanism	  for	  this	  beneficial	  effect.	  .	  A	  major	  limitation	  of	  these	  studies	  was	  the	  need	  to	  perform	  skin	  biopsies	  to	  measure	  anti	  microbial	  peptide	  levels.	  	  	  	  This	  meant	  that	  studies	  were	  small	  and	  none	  had	  been	  performed	  in	  pediatric	  patients	  with	  AD.	  	  	  Therefore,	  this	  study	  was	  designed	  with	  the	  following	  aims:	  
- To	  determine	  the	  extent	  of	  VD	  deficiency	  in	  pediatric	  AD	  patients	  
- To	  investigate	  whether	  there	  was	  a	  difference	  in	  VD	  status	  between	  AD	  and	  ADEH	  patients.	  	  
- To	  examine	  lesional	  and	  non-­‐lesional	  LL-­‐37	  levels	  in	  AD	  and	  ADEH	  patients	  at	  the	  skin	  surface,	  by	  a	  novel,	  non-­‐invasive	  technique.	  
- To	  determine	  IgE	  levels	  and	  serum	  calcium	  levels	  	  
- To	   establish	   whether	   VD	   supplementation	   would	   improve	   the	   clinical	  severity	   of	   ADEH	   patients	   in	   particular,	   as	   well	   as	   AD	   patients,	   when	   no	  other	  variable	  is	  changed	  in	  clinical	  practice.	  





















II. Chapter	  Two:	  Materials	  and	  Methods	  
	  
II.I.	  	  Study	  design:	  
	  A	  practice	  evaluation	  study	  was	  performed	  in	  the	  Dermatology	  department	  of	  the	  Sheffield	  Children’s	  Hospital.	  Ninety	  children	  were	  diagnosed	  with	  AD	  based	  on	  the	  UK	  Working	  Party’s	  diagnostic	  criteria	  upon	  routine	  attendance	  to	  the	  dermatology	  clinic	  (Williams,	  Burney	  et	  al.	  1996)	  .	  These	  children	  were	  then	  stratified	  further	  to	  either	  AD	  or	  ADEH.	  ADEH	  patients	   included	  were	   those	   that	  had	  been	  diagnosed	  clinically	  as	  having	  herpetic	  lesions	  by	  a	  dermatologist	  and	  treated	  for	  at	  least	  six	  months	  with	  antiviral	  medications.	  Both	  groups	  were	  screened	   for	  VD	  deficiency.	  Total	  IgE	  and	  serum	  calcium	  levels	  were	  also	  checked.	  	  Patients	  with	  VD	  deficiency	  were	   then	   assessed	   clinically	   on	   a	   follow	  up	   visit	   by	  means	   of	   the	   SCORAD	   index	   by	   a	   single	   dermatologist,	   and	   the	   patient-­‐oriented	  eczema	  measure	  (POEM)	  scores	  were	  also	  determined.	  In	  addition,	  samples	  of	  skin	  surface	  cells	  were	  collected	  using	  a	  novel	  non-­‐invasive	  technique	  for	  evaluation	  of	  LL-­‐37	   levels	   from	   lesional	   and	  non-­‐lesional	   sites	   of	   the	  VD	  deficient	  AD	  patients.	  Quantification	   of	   LL-­‐37	   in	   superficial	   skin	   samples	   was	   performed	   as	   explained	  below.	  	  
Taking	   the	   International	   Osteoporosis	   Foundation’s	   	   (IOF)	   recommendations	  (Dawson-­‐Hughes,	  Mithal	  et	  al.	  2010)	  ,	  levels	  >75	  nmol/L	  were	  defined	  as	  sufficient	  VD	   levels.	   Levels	   <50	   nmol/L	   were	   deemed	   deficient;	   and	   supplementation	  commenced.	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  Levels	  of	  50-­‐75	  nmol/L	  were	  considered	  suboptimal	  and	  corrected	  with	  over	   the	  counter	   (OTC)	  multivitamin	  preparations	  containing	   the	  100%	  RDA	  of	  VD.	  Those	  that	   were	   considered	   deficient	   were	   supplemented	   depending	   upon	   the	   level	   of	  deficiency	  and	  age	  (6000	  IU	  of	  cholecalciferol	  daily	   in	  ages	  1-­‐12	  years;	  10,000	  IU	  daily	   for	  12-­‐18	  years	  of	  age)	  according	   to	   the	  British	  National	  Formulary	  (British	  Medical	   Association	   and	  Royal	   Pharmaceutical	   Society	   of	   Great	   Britain	   2011)	   for	  two	  months.	  	  Patients	   continued	   on	   the	   same	   topical	   and	   oral	   medications.	   No	   treatment	   was	  changed,	  or	  withheld	  during	  this	  period,	  and	  patients	  were	  treated	  accordingly	  as	  usual	   clinical	   practice.	   In	   the	   event	   that	   a	   patient	   needed	   to	   commence	   new	  treatment,	   such	   as	   immune-­‐suppressants	   or	   anti	   viral	   medication,	   VD	  supplementation	   was	   commenced,	   however	   the	   patient	   was	   not	   included	   in	   the	  final	  analysis.	  Therefore	  newly	  diagnosed	  ADEH	  patients	  were	  not	  included	  in	  the	  final	  analysis.	  
On	   the	   follow	   up	   visit	   after	   two	   months	   of	   supplementation,	   SCORAD	   was	  reassessed	  by	   the	  same	  dermatologist	  and	  POEM	  was	  repeated.	  Serum	  VD	   levels,	  total	   IgE	   level	   and	   serum	   calcium	   levels	  were	   rechecked.	   In	   addition,	   samples	   of	  skin	   surface	   cells	   were	   collected	   again	   from	   lesional	   and	   non-­‐lesional	   sites	   for	  reassessment	  of	  LL-­‐37	  levels.	  




II.II	  Evaluation	  of	  clinical	  severity	  
II.II.I	  SCORAD	  
SCORAD	   is	   a	   system	   that	   incorporates	   three	   components:	   extent	   of	   involvement,	  intensity	   and	   subjective	   systems	   as	   indicators	   of	   quality	   of	   life	   (European	   Task	  Force	   On	   Atopic	   1993).	   AD	   patients	   in	   this	   study	  were	   evaluated	   on	   these	   three	  components	  in	  the	  dermatology	  clinic.	  
Extent	  of	  area	  involved	  is	  evaluated	  based	  on	  the	  rule	  of	  nine,	  originally	  proposed	  for	  assessment	  of	  burns	  (Berkow	  1924).	  The	  lesions	  included	  in	  the	  assessment	  are	  only	   inflammatory	   patches	   of	   eczema	   and	   not	   general	   dryness,	   and	   are	   directly	  plotted	  onto	  a	  printed	  figure	  in	  the	  evaluation	  sheet.	  
The	   intensity	   items	   are	   composed	   of	   six	   criteria:	   erythema,	   edema/papulation,	  oozing/crusting,	   excoriations,	   lichenification	   and	   dryness.	   For	   evaluation	   of	  intensity,	   for	   each	   item	   an	   area	   is	   chosen	   on	   the	   patient	   that	   is	   regarded	  representative	  of	  all	   the	   lesions	   in	   the	  patient.	  Therefore,	   the	  worst	  area	  affected	  should	  be	  excluded	  (European	  Task	  Force	  On	  Atopic	  1993).	  	  






Figure	  II.	  1:	  SCORAD;	  extent	  of	  area	  involved	  in	  AD.	  Rule	  of	  nine	   is	  applied	  to	  evaluate	   the	  extent	  of	  AD	   in	  a	  patient.	   In	   this	  method,	  both	  the	  front	  and	  back	  of	  patient	  is	  plotted.	  In	  patients	  over	  two	  years	  of	  age,	  the	  head	  accounts	  for	  4.5%;	  the	  trunk	  for	  18	  %	  of	  body	  surface	  area	  on	  each	  side;	  the	  upper	  limbs	  for	  9	  %,	  each	  of	  the	  lower	  limbs	  for	  9%.	  Each	  hand	  accounts	  for	  1	  %;	  the	  groin	  accounts	  for	  1	  %	  as	  well.	  The	   figures	   in	   parentheses	   are	   for	   children	   less	   than	   2	   years	   of	   age,	   where	   the	   head	  accounts	  for	  8.5%,	  and	  the	  posterior	  aspect	  of	  the	  lower	  limbs	  for	  6%	  each.	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II.II.III	  The	  Patient	  Oriented	  Eczema	  Measure	  (POEM)	  
	  
POEM	   is	   a	   measure	   developed	   for	   the	   self-­‐assessment	   and	   monitoring	   of	   AD	  (Charman,	  Venn	  et	  al.	  2004).	  It	  is	  important	  due	  to	  the	  fact	  it	  provides	  insight	  into	  the	  patient’s	  perspective	  on	  their	   illness	  and	  their	  experience.	   It	  mainly	  examines	  symptom	  frequency	  rather	  than	  overall	  severity,	  which	  is	   important	  for	  assessing	  relapses	  and	  remissions,	  as	  well	  as	  general	  quality	  of	  life.	  
AD	  patients	  completed	  a	  questionnaire	  consisting	  of	  seven	  questions	  (Figure	  II.2),	  addressing	  issues	  such	  as	  itchiness,	  dryness,	  sleep	  loss,	  bleeding	  and	  infection	  signs	  such	  as	  weeping	  and	  oozing.	  All	  answers	  were	  allocated	  a	  score	  from	  which	  a	  total	  score,	  maximum	  28,	  is	  determined.	  
	  












II.III.	   Evaluation	   of	   Cathelicidin	   levels	   (LL-­‐37)	   in	   the	   stratum	  
corneum	  	  
II.III.I	  Collection	  of	  superficial	  skin	  samples	  
Sterile	   nylon	   brushes	   (Cytotak	   Transwab	   brushes,	  Medical	  Wire	   and	   Equip.	   LTD,	  UK)	  were	  used	  to	  collect	  surface	  cells	  of	  the	  stratum	  corneum.	  Brushes	  were	  gently	  brushed	   against	   the	   skin	   surface,	   then	   placed	   in	   1.5	   ml	   micro	   tubes	   (Sarstedt,	  Aktiengesellschaft	   and	   Co.,	   Germany)	   and	   placed	   in	   a	   –	   80	   freezer	   until	   analysis	  (Forma	  Scientific,	  Inc.	  USA).	  	  
II.III.II	  Analysis	  of	  LL-­‐37	  levels	  in	  superficial	  skin	  samples	  
Enzyme-­‐Linked	   Immuno-­‐Sorbent	   Assay	   (ELISA),	   is	   a	   popular	   type	   of	   analytic	  biochemistry	   assay	   used	   to	   detect	   the	   presence	   of	   an	   antigen	   in	   a	   liquid	   sample	  (Ueda	   2007).	   Detecting	   antigens	   in	   a	   sample	   is	   through	   the	   following	   steps:	   The	  specific	   antigens,	   presumed	   to	   be	   in	   the	   sample	   adhere	   to	   a	   surface.	   Then	   an	  antibody,	   specifc	   to	   these	   antigens,	   is	   placed	   over	   the	   surface	   to	   allow	   antigen-­‐antibody	   binding.	   This	   specific	   antibody	   is	   connected	   to	   an	   enzyme.	   The	   enzyme	  then	   reacts	  with	   a	   substrate	  present	   in	   the	   last	   solution	   added,	   and	   this	   reaction	  produces	   a	   color	   change	   in	   the	   substrate,	   which	   is	   then	   read	   by	   a	  spectrophotometer.	  
To	   prepare	   the	   samples,	   an	   extraction	   buffer	   (10	  mM	  disodium	  phosphate/0.2%	  sodium	   dodecyl	   sulphate/	   0.5%	   propylene	   glycol)	   at	   pH	   7.4	   was	   prepared	  (Hendrix,	  Miller	  et	  al.	  2007).	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Protease	   inhibitors	   (Complete	  mini,	   Roche,	   Germany)	  were	   then	   added	   (1	   tablet	  per	  10	  ml	  of	  extraction	  buffer)	  to	  prevent	  undue	  proteolysis	  of	  LL-­‐37.	  These	  tablets	  contain	   the	   following	   enzymes:	   Pancreas-­‐extract	   0.02	   mg/ml,	   Pronase	   0.005	  mg/ml,	   Thermolysin	   0.0005	  mg/ml,	   Chymotrypsin	   0.003mg/ml	   and	   Papain	   0.33	  mg/ml.	  	  To	   each	   micro	   tube	   of	   sample,	   each	   containing	   three	   brushes,	   800	   µL	   of	   the	  prepared	   extraction	   buffer	   was	   added.	   The	   samples	   were	   then	   sonicated	   for	   30	  minutes	  in	  a	  sonication	  water	  bath	  (Ultrawave	  ltd.,	  UK).	  The	  brushes	  were	  removed	  from	  the	  micro	  tubes	  and	  discarded;	  275	  µL	  of	  each	  sample	  was	  placed	  in	  duplicate	  wells	  in	  a	  96	  multi-­‐well	  plate,	  pre-­‐coated	  in	  the	  LL-­‐37	  capture	  antibody	  provided	  in	  the	  ELISA	  kit	  (Human	  LL-­‐37	  ELISA	  kit,	  Hycult	  biotech,	  The	  Netherlands).	  Standards	  of	   LL-­‐37	   of	   known	   concentrations,	   prepared	   according	   to	   the	   manufactures	  guidelines,	  were	  also	  loaded	  on	  to	  the	  plate	  (Table	  2).	  The	  plate	  was	  then	  incubated	  for	   one	   hour	   at	   room	   temperature.	   The	   plate	   was	   washed	   four	   times	   with	  wash/dilution	  buffer	  supplied	   in	  the	  kit.	  Boiotinylated	  tracer	  antibody	  was	  added	  (100	  μL	   to	  each	  well),	  and	   the	  plate	  was	   incubated	  again	   for	  one	  hour.	  The	  wash	  procedure	   was	   then	   repeated	   as	   before,	   after	   which	   100	   µL	   of	   streptavidin-­‐peroxidase	  was	  added	  to	  each	  well	  and	  incubated	  for	  an	  hour.	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Concentration	  of	  
Standards	  (ng/ml)	  	  
Volume	  of	  standard	   Volume	  of	  
Wash/dilution	  
Buffer	  
100	   	  	  	  	  	  	  150	  μl	   230	  μl	  
33	   125	  μl	   250	  μl	  
11	   125	  μl	   250	  μl	  
3.7	   125	  μl	   250	  μl	  
1.2	   125	  μl	   250	  μl	  
0.4	   125	  μl	   250	  μl	  
0.1	   125	  μl	   250	  μl	  
0	   0	   250	  μl	  
	  


















	  Tetra	  methyl	  benzidine	  substrate,	  supplied	  in	  the	  kit,	  was	  added	  after	  repeating	  the	  wash	   procedure	   above,	   and	   plate	   was	   incubated	   for	   30-­‐40	   minutes.	   The	   stop	  solution	  oxalic	  acid	  was	  added	  to	  each	  well	  to	  stop	  the	  reaction,	  and	  the	  plate	  was	  read	   using	   a	   Spectramax	   ME5	   plate	   reader	   (Molecular	   devices,	   LLC,	   USA)	   at	   a	  wavelength	  of	  450	  nm.	  
	  The	  concentration	  of	  LL-­‐37	  in	  each	  sample	  was	  extrapolated	  from	  a	  standard	  curve	  generated	  with	  the	  absorbance	  readings	  from	  the	  standards	  included	  on	  each	  assay	  plate.	  These	   readings,	   in	  addition	   to	   the	   total	  protein	   readings	  obtained	   from	   the	  BCA	  assay	  below,	  were	  used	  to	  determine	  the	  amount	  of	  LL	  37	  per	  gram	  of	  protein.	  
	  
II.III.III	  The	  Bicinchoninic	  Acid	  (BCA)	  analysis	  
	  





Standards	  (μl/ml)	   Volume	  of	  BSA	   Volume	  of	  de	  ionized	  H2o	  
30	   300	  μl	   9.7	  ml	  
20	   200	  μl	   9.8	  ml	  
15	   150	  μl	   9.85	  ml	  
10	   100	  μl	   9.90	  ml	  
5	   50	  μl	   9.95	  ml	  
2	   20	  μl	   9.98	  ml	  
1	   10	  μl	   9.99	  ml	  
0	   0	   10.00	  ml	  
	  
Table	  3:	  Concentrations	  of	  Standards	  used	  in	  the	  BCA	  assay	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Samples	  were	  loaded	  into	  the	  micro	  well	  plates	  in	  duplicates;	  a	  two-­‐fold	  stepwise	  dilution	  was	  then	  performed.	  The	  plate	  was	  then	  incubated	  at	  60	  °C	  for	  two	  hours,	  and	   then	   read	   with	   a	   spectrophotometer,	   at	   a	   wavelength	   of	   562	   nm.	   The	   total	  protein	  concentration	  is	  proportional	  to	  the	  degree	  of	  change.	  	  The	   absorbance	   readings	   of	   the	   standards	   were	   then	   plotted	   against	   the	  concentrations	   of	   standards,	   and	   analyzed	   by	   linear	   regression	   using	   Microsoft	  Excel	   to	   obtain	   a	   linear	   calibration	   curve.	   The	   absorbencies	   of	   the	   samples	  were	  then	  extrapolated.	  	  
II.IV.	  Statistical	  Analyses:	  
	  Statistical	  analysis	  was	  performed	  using	  Prism	  5	  (Graph	  Pad	  Prism	  Software,	  Inc.,	  a	  Jolla,	  USA).	  SCORAD	  and	  POEM	  results	  were	  analyzed	  by	  two	  tailed	  paired	  students	  t-­‐test.	   LL-­‐37,	   IgE	   and	   serum	   calcium	   results	   were	   analyzed	   using	   an	   unpaired	  students	   t-­‐test.	   One-­‐way	   analysis	   of	   variance	   (ANOVA)	  was	   used	   to	   analyze	   data	  stratified	  according	  to	  SCORAD.	  Post	  hoc	  comparisons	  were	  done	  with	  Bonferroni’s	  multiple	  comparisons	  test.	  Level	  of	  significance	  was	  set	  at	  p	  <0.05.	  All	  values	  were	  expressed	  as	  mean	  +	  standard	  error	  of	  the	  mean	  (SEM).	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III. Chapter	  Three:	  Results	  
	  
III.I.	  Patient	  demographics:	  
	  Ninety	   children	  with	   a	  mean	   age	   of	   9	   (ages	   1-­‐18)	  were	   screened,	   of	  which	   52%	  were	  male	  and	  48%	   female.	  The	  demographics	  were	  as	   follows:	   	  63%	  Caucasian,	  27%	   Asian	   descent,	   4%	   of	   mixed	   race,	   4%	   Chinese	   and	   2%	   of	   African	   descent	  (Table	  2).	  Fifty	  percent	  of	  the	  patients	  screened	  were	  classified	  as	  ADEH	  and	  were	  either	  under	  treatment	  or	  had	  been	  treated	  previously	  with	  anti-­‐viral	  medication.	  
Eleven	  of	   the	  patients	  were	  on	   immunosuppressant	   treatment	   for	   at	   least	   a	   year	  prior	   to	   the	   study.	   The	   majority	   of	   the	   children	   were	   on	   a	   combination	   of	  emollients,	   topical	   corticosteroids	   and	   topical	   calcineurin	   inhibitors;	   only	   two	  patients	  were	  just	  on	  emollient	  therapy.	  






Characteristic	   N	  (%)	  
Gender:	  	  Females	  Males	  
	  47	  (52%)	  43	  (48%)	  
Ethnicity:	  	  Caucasian	  Asian	  Chinese	  African	  Mixed	  
	  57(63%)	  24	  (27%)	  3	  (4%)	  2	  (2%)	  4	  (4%)	  
Clinical	  classification:	  AD	  ADEH	  
	  45	  (50%)	  45	  (50%)	  
Healthy	  VD	  levels	  Unhealthy	  VD	  levels:	  -­‐	  Sub	  optimal	  VD	  (50-­‐75nmol/l)	  -­‐	  Deficient	  VD	  (<50nmol/l)	  -­‐	  Severely	  deficient	  VD	  (<25nmol/l)	  
15	  (17	  %)	  75	  (83%)	  23	  (26	  %)	  35	  (39%)	  17	  (18%)	  
	  
Table	  4:	  Demographics	  of	  the	  AD	  patients	  screened	  in	  the	  clinic.	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Caucasian	   8	  (47%)	   24	  (68%)	   16	  (70%)	   12	  (80%)	  
Asian	   7	  (41%)	   7	  (20	  %)	   3	  (13%)	   3	  (20%)	  
Chinese	   1	  (6	  %)	   1	  (3	  %)	   1	  (4	  %)	   0	  
African	   0	   0	   3	  (13	  %)	   0	  
Mixed	  origin	   1	  (6%)	   3	  (9	  %)	   0	   0	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Characteristic	   N	  (%)	  
Gender:	  	  Females	  Males	   	  21	  (45%)	  26	  (55%)	  
Ethnicity:	  	  Caucasian	  Asian	  Chinese	  African	  Mixed	  
	  25	  (53%)	  14	  (30%)	  3	  (6%)	  1	  (2%)	  4	  (9%)	  
Clinical	  classification:	  AD	  ADEH	   	  12	  (26%)	  35	  (74%)	  
Unhealthy	  VD	  levels:	  -­‐	  Sub	  optimal	  VD	  (50-­‐75nmol/l)	  -­‐	  Deficient	  VD	  (<50nmol/l)	  -­‐	  Severely	  deficient	  VD	  (<25nmol/l)	  
47	  12	  (25%)	  23	  (50%)	  12	  (25%)	  
	  















Caucasian 4	  (33%) 13	  (57%) 8	  (67%) 
Asian 6	  (50%) 6	  (26%) 2	  (17%) 
Chinese 1	  (8%) 1	  (4%) 1	  (8%) 
African 0 0 1	  (8%) 
Mixed	  origin 1	  (8%) 3	  (13%) 0	   
	  
Table	   7:	   Classification	   of	   VD	   status	   according	   to	   ethnic	   group	   in	   the	   AD	   patients	  
included	  in	  the	  practice	  evaluation	  study.	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III.II.	  Pre-­‐supplementation	  assessment:	  	  In	  the	  original	  population	  screened,	  only	  two	  of	  the	  45	  ADEH	  patients	  had	  sufficient	  VD	   levels	   by	   current	   standards.	   ADEH	   patients	   were	   found	   to	   have	   significantly	  lower	   VD	   levels	   than	   AD	   patients	   (p	   <0.0001,	   mean	   ADEH	   score=	   37.27	   ±	   2.95,	  mean	  AD	  score=	  60.81±4.12,	  unpaired	  t-­‐test,	  Figure	  III.2).	  
Using	  SCORAD,	  the	  47	  remaining	  patients	  included	  in	  the	  study	  were	  classified	  into	  three	   groups	   based	   on	   severity:	   mild	   <25,	   moderate	   25-­‐50	   and	   severe	   >50,	   as	  described	   in	  previous	   studies,	  which	  will	   be	  discussed	   in	  detail	   in	   the	  discussion	  chapter.	  VD	  levels	  were	  found	  to	  be	  significantly	  different	  between	  the	  groups	  by	  one-­‐way	  ANOVA	  (Figure	  III.3,	  p	  =	  0.016,	  means	  30.6	  ±	  4.5,	  40.4	  ±	  2.72,	  and	  56.7±	  10.31	   respectively).	   Bonferroni’s	   post-­‐test	   revealed	   a	   statistically	   significant	  difference	   in	  VD	   levels	  between	  children	  with	   severe	  and	  mild	  AD.	  VD	   levels	  and	  SCORAD	   also	   showed	   a	   significant	   inverse	   correlation	   (p	   =	   0.014,	   Pearson’s	  correlation	  coefficient	  r=-­‐	  0.4,	  Figure	  III.4).	  





























Figure	  III.	  3:	  Classification	  of	  patients	  based	  on	  SCORAD.	  AD	  patients	   (47)	  were	  classified	   into	   three	  groups:	   severe	  AD	  (>50,	  n=13),	  moderate	  AD	  (25-­‐50,	  n=	  30),	  and	  mild	  AD	  (<25,	  n=4).	  VD	  levels	  were	  significantly	  different	  (p	   	  =	  0.016,	  mean	  severe	  AD=	  56.7	  ±	  10.31,	  mean	  moderate	  score=	  40.4	  ±	  2.72,	  mean	  mild	  score=30.6	  ±	  4.5;	   one	   way	   ANOVA).	   Post-­‐test	   with	   Bonferonni’s	   multiple	   comparisons	   showed	   a	  significant	   difference	   between	   mild	   and	   severe	  scores.	  


















	  	  	  
	  
	  
Figure	  III.	  4:	  Correlation	  of	  SCORAD	  and	  VD	  levels.	  Correlation	  of	  VD	   levels	   and	  SCORAD	  also	   showed	  a	   significant	   inverse	   relationship	   (p	   =	  0.014,	  Pearson’s	  correlation	  coefficient	  r=-­‐	  0.4,	  n=47).	  




























































Figure	  III.	  7:	  LL-­‐37	  levels	  according	  to	  SCORAD.	  LL-­‐37	  levels	  were	  stratified	  according	  to	  SCORAD	  severity	  into	  mild,	  moderate	  and	  severe.	  Analysis	  by	  one-­‐way	  ANOVA	  showed	  a	  significant	  difference	  in	  LL-­‐37	  levels	  between	  mild,	  moderate	   and	   severe	   SCORAD	   (1.15	  ±	  0.39	  μg/g,	   0.47	  ±	  0.09	  μg/g	   and	  0.34	  ±	  0.09	  μg/g	  respectively,	  p	  =0.018).	  Bonferroni’s	  post-­‐test	  revealed	  a	  significant	  relationship	  between	  both	  mild	  and	  moderate,	  and	  mild	  and	  severe	  groups	  (p<	  0.05).	  
	  	  	  	  































































Figure	  III.	  9:	  LL-­‐37	  levels	  in	  AD	  and	  ADEH	  patients.	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III.III.	  Post-­‐supplementation	  assessment:	  	  After	  two	  months	  of	  VD	  supplementation,	  VD	  levels	  showed	  a	  significant	  two-­‐fold	  increase	   from	   mean	   level	   37.99	   ±	   2.8	   to	   level	   84.93	   ±	   11.93	   nmol/l,	   however	  remained	  within	  normal	  levels	  (p	  <	  0.0001,	  unpaired	  t-­‐test,	  Figure	  III.11).	  	  Similarly,	   SCORAD	   scores	   also	   showed	   significant	   improvement	   with	   a	   mean	  reduction	   of	   42.3%	   (p	   <	   0.0001,	   paired	   t-­‐test,	   Figure	   III.12).	   	   Stratification	   of	  patients	   into	   ADEH	   and	   AD	   also	   revealed	   significant	   reduction	   in	   SCORAD	   (p	  <0.0001,	  ADEH	  from	  mean	  score	  48.67	  ±	  1.4	   to	  27.78	  ±	  1.9;	  AD	  from	  mean	  score	  35.69	  ±	  2.9	  to	  20.46	  ±	  2.68;	  Figure	  III.13,	  paired	  t-­‐test).	  





Figure	  III.	  11:	  	  Comparison	  of	  VD	  levels.	  After	   two	  months	   of	   VD	   supplementation,	   VD	   levels	   showed	   a	   significant	   increase	   from	  mean	   level	   37.99	   ±	   2.8	   to	   level	   84.93	   ±	   11.93	   nmol/l,	   however	   remained	  within	   normal	  levels	  (p	  <	  0.0001,	  unpaired	  t-­‐test).	  	  
	  





































Figure	  III.	  13:	  SCORAD	  in	  AD	  and	  ADEH	  patients.	  ADEH	  patients	  (left	  graph)	  showed	  a	  significant	  reduction	  in	  SCORAD	  after	  two	  months	  of	  VD	   supplementation	   (from	   mean	   score	   48.67	   ±	   1.4	   to	   27.78	   ±	   1.9;	   paired	   t-­‐test).	   AD	  patients	   (right	  graph)	  also	   showed	  a	   significant	   reduction	   in	  SCORAD	  (	   from	  mean	  score	  35.69	  ±	  2.9	  to	  20.46	  ±	  2.68;	  paired	  t-­‐test).	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Figure	  III.	  14:	  Stratification	  of	  SCORAD	  based	  upon	  type	  of	  VD	  supplement.	  Stratification	  of	  patients	   into	   those	   treated	  with	  OTC	  VD	  supplements	   (left	  graph,	  n=	  12)	  and	  those	  whom	  received	  the	  therapeutic	  dose	  (right	  graph,	  n=	  35)	  revealed	  both	  groups	  to	   have	   significantly	   reduced	   SCORAD	   scores	   after	   two	   months	   of	   supplementation	  (OTC=40.7%	   SCORAD	   reduction	   from	   mean	   score	   38.8	   ±	   3.79	   to	   23.9	   ±	   3.23;	  Cholecalciferol=	  42.2%	  reduction	  from	  mean	  score	  46.53	  ±	  1.55	  to	  27.14	  ±	  1.94;	  paired	  t-­‐test).	  	  
Therapeutic VD


































Figure	   III.	   15:	   The	   percentage	   of	   SCORAD	   reduction	   in	   OTC	   and	   Cholecalciferol	  

























Figure	  III.	  16:	  POEM	  scores	  after	  two	  months	  of	  VD	  supplements.	  POEM	  scores	  in	  47	  AD	  patients	  showed	  a	  significant	  reduction	  from	  mean	  score	  18.3	  ±	  0.8	  to	  9.2	  ±	  0.7	  (mean	  reduction=46.6%)	  after	  two	  months	  of	  supplementation	  (paired	  t-­‐test).	  
	  
	  











Figure	  III.17:	  POEM	  scores	  in	  AD	  and	  ADEH	  patients.	  POEM	   in	   AD	   patients	   showed	   a	   significant	   reduction	   after	   two	   months	   of	   VD	  supplementation	   (from	  mean	  score	  14.92	  ±	  1.4	   to	  7.67	  ±	  1.11,	  p	  =	  0.0009,	  paired	   t-­‐test).	  ADEH	  pateints	  also	  showed	  a	  significant	  reduction	  in	  the	  POEM	  scores	  (from	  mean	  score	  19.73	  ±	  0.92	  to	  10.52	  ±	  0.83,	  p	  <	  0.0001,	  paired	  t-­‐test).	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LL-­‐37	   levels	   showed	   a	   significant	   four	   fold	   increase	   after	   two	   months	  supplementation	  (p	  =	  0.0004,	  unpaired	  t-­‐test,	  Figure	  III.18).	  Both	  lesional	  and	  non-­‐lesional	  LL-­‐37	  showed	  a	  significant	  increase	  post	  supplementation	  (Figure	  III.19).	  
Serum	   calcium	   levels	   also	   showed	   a	   significant	   increase	   (p	   =	   0.0037,	   unpaired	   t-­‐test,	  Figure	   III.20),	  which	  differed	   from	  IgE	   levels,	  which	  did	  not	  show	  significant	  change	  (p	  =	  0.84).	  	  




Figure	  III.	  18:	  LL-­‐37	  levels	  in	  AD	  patients.	  After	   two	  months	   of	   supplementation	  with	  VD,	   LL-­‐37	   levels	   increased	   significantly	   from	  mean	  LL-­‐37	  level=	  0.46	  ±	  0.06	  μg/g	  to	  1.98	  ±	  0.44	  μg/g	  	  (p=	  0.0004,	  unpaired	  t-­‐test).	  	  	  	  



















Figure	  III.	  19:	  Lesional	  and	  non-­‐lesional	  LL-­‐37	  levels	  in	  AD	  Left	  graph:	  LL-­‐37	  sampled	  at	  lesional	  sites	  showed	  a	  significant	  increase	  from	  mean	  LL-­‐37	  level	  0.504±	  0.104	  μg/g	  to	  mean	  level	  2.57	  ±	  0.82 μg/g	   	  (p	  =	  0.0072).	  Right	  graph:	  LL-­‐37	  sampled	  from	  non-­‐lesional	  sites	  also	  showed	  a	  significant	  increase	  from	  mean	  level	  0.405	  ±	  0.08	  μg/g	  to	  1.47	  ±	  0.35	  μg/g	  	  (p	  =	  0.046,	  unpaired	  t-­‐test).	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Figure	  III.	  20:	  Serum	  calcium	  and	  IgE	  levels.	  Top	  graph:	  serum	  calcium	  also	  showed	  a	  significant	  increase	  from	  mean	  level	  2.25	  ±	  0.011	  mmol/l	   to	  2.3	  ±	  0.013	  mmol/l	   (p	  =	  0.0037,	  unpaired	  t-­‐test).	  Bottom	  graph:	   	   IgE	   level	  did	  not	  show	  significant	  change	  from	  mean	  score	  7010	  ±	  2370	  nmol/l	  to	  7824	  ±	  3221nmol/l	  (p	  =0.84,	  unpaired	  t-­‐test).	  









































	  	  	  	  	  	  	  	  	  
















IV. Chapter	  Four:	  Discussion	  
	  
IV.I.	  Defining	  VD	  deficiency	  	  	  VD	  deficiency	   is	  now	  recognized	   to	  be	  a	  worldwide	  problem	  (Ford,	  Graham	  et	  al.	  2006;	   Hypponen	   and	   Power	   2007).	   Approximately	   50	   %	   of	   the	   adult	   British	  population	   have	   insufficient	   levels	   of	   VD	   (<	   50nmol/l)	   (Hypponen	   and	   Power	  2007).	   A	   further	   16%	   are	   severely	   deficient	   during	   winter	   and	   spring	   months	  (Ford,	  Graham	  et	  al.	  2006).	  In	  children	  less	  than	  five	  years	  of	  age,	  the	  incidence	  of	  symptomatic	  VD	  deficiency	   (identified	  by	  either	   radiographic	   evidence	  of	   rickets,	  or	   by	   diagnosis	   of	   hypocalcemic	   convulsions)	   was	   found	   to	   be	   7.5	   per	   100,	   000	  (Callaghan,	   Moy	   et	   al.	   2006).	   Another	   recent	   study	   in	   Scotland	   found	   an	   annual	  incidence	  of	   23	   cases	   of	   symptomatic	  VD	  deficiency	   in	   children	   from	  2002-­‐2007,	  and	  an	  increase	  to	  42	  cases	  in	  2008	  (Ahmed,	  Franey	  et	  al.	  2011).	  	  
In	  Kuwait,	  40%	  of	  mothers	  and	  60%	  of	  neonates	  were	  found	  to	  be	  deficient	  on	  the	  day	   of	   delivery	   (Molla,	   Al	   Badawi	   et	   al.	   2005).	   Seventy	   five	   percent	   of	   young	  Kuwaiti	  women	  were	  found	  to	  consume	  less	  than	  two	  thirds	  of	  the	  recommended	  daily	  allowance	  (RDA)	  of	  VD	  (Alshawi	  1992).	  




The	   increasing	   awareness	   of	   the	   value	   of	   VD	   has	   lead	   to	   controversy	   over	   the	  definition	   of	   VD	   deficiency.	   Recently	   the	   Institute	   of	   Medicine	   (IOM)	   defined	   VD	  sufficient	  at	  50nmol/L,	  and	  recommended	  a	  daily	  intake	  of	  600	  IU/day	  for	  ages	  1-­‐70.	  A	  higher	  intake	  was	  recommended	  for	  the	  elderly	  (800	  IU/day).	  	  (Ross,	  Manson	  et	  al.	  2011).	  These	  levels,	  however,	  were	  estimated	  sufficient	  with	  respect	  to	  bone	  requirements	   only.	   Evidence	   for	   extra	   skeletal	   requirements	   was	   deemed	  insufficient	   and	   inconclusive,	   and	   as	   such	   the	   IOM	   encouraged	  more	   research	   in	  this	  area.	  
The	   IOM	   recommendations	   have	   already	   been	   challenged	   by	   many	   (Bischoff-­‐Ferrari.	   H	   and	   W	   2011;	   Hollis	   and	   Wagner	   2011;	   Schwalfenberg	   and	   Whiting	  2011),	  declaring	   these	   levels	   too	   low	   for	  optimal	  bone	  health.	   Indeed,	   trials	  have	  determined	   that	   levels	   <	   60	   nmol/l	   lead	   to	   a	   19%	   increase	   in	   fracture	   falls	  (Bischoff-­‐Ferrari,	   Dawson-­‐Hughes	   et	   al.	   2009).	   Levels	   less	   than	   75	   nmol/l	   were	  associated	  with	  an	  increased	  risk	  in	  hip	  fractures	  (Bischoff-­‐Ferrari	  2009).	  
Furthermore,	  arguments	  have	  also	  been	  made	  against	  the	  insufficiency	  of	  this	  level	  to	  prevent	  extra	  skeletal	  VD	  deficiency	  effects	  (Holick	  2011).	  A	  meta-­‐analysis	  of	  18	  RCTs	   studying	   the	   effect	   of	   VD	   supplementation	   on	  mortality	   concluded	   that	   VD	  supplements	  appeared	   to	  reduce	   the	  risk	  of	  mortality	   (Autier	  and	  Gandini	  2007).	  Levels	   less	   than	   44.5	   nmol/l	   have	   been	   associated	   with	   26%	   increased	   risk	   of	  mortality	   (Melamed,	  Michos	   et	   al.	   2008).	   An	  RCT	   on	   334	   children	   found	   that	   VD	  supplementation	  to	  levels	  greater	  than	  75	  nmol/l	  were	  associated	  with	  a	  reduction	  in	  influenza	  A	  incidence	  in	  school	  children	  (Urashima,	  Segawa	  et	  al.	  2010).	  Another	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RCT	   showed	   VD	   levels	   over	   75	   nmol/l	   could	   improve	   vascular	   stiffness	   in	  adolescents	  (Dong,	  Stallmann-­‐Jorgensen	  et	  al.	  2010).	  	  
De	  Boer	  and	  colleagues	  in	  a	  recent	  study	  evaluated	  the	  relationship	  between	  serum	  VD	  levels	  and	  the	  risk	  of	  hip	  fractures,	  myocardial	  infarctions,	  cancer	  and	  mortality	  (de	   Boer,	   Levin	   et	   al.	   2012).	   The	   conclusion	   reached	   was	   that	   levels	   of	  approximately	  50	  nmol/l	  are	  associated	  with	  an	  increased	  risk	  for	  multiple	  disease	  outcomes.	  Hence	  the	  International	  Osteoporosis	  Foundation	  (IOF)	  recommended	  a	  level	   of	   75nmol/L	   (Dawson-­‐Hughes,	   Mithal	   et	   al.	   2010),	   as	   did	   the	   Endocrine	  Society	  Clinical	  Practice	  Guideline	  (Holick,	  Binkley	  et	  al.	  2011).	  
Taking	  all	  this	  into	  account,	  only	  patients	  with	  levels	  >	  75nmol/l	  were	  considered	  to	  have	  a	  healthy	  VD	  status,	  levels	  <50	  nmol/l	  were	  considered	  deficient.	  Therefore	  83%	  percent	  of	  AD	  children	  in	  this	  study	  were	  found	  to	  have	  unhealthy	  VD	  levels,	  compared	   to	   40%	   in	   healthy	   children:	   57%	  were	  deficient,	   a	   finding	   similar	   to	   a	  previous	   RCT	   on	   AD	   children	   (Javanbakht,	   Keshavarz	   et	   al.	   2011).	   However,	   if	  adjusting	  the	  cut	  off	  level	  at	  50	  nmol/l	  in	  accordance	  with	  IOM	  recommendations,	  57%	   of	   the	   AD	   patients	   would	   still	   be	   considered	   higher	   than	   levels	   found	   in	  healthy	  individuals	  (Gordon,	  DePeter	  et	  al.	  2004).	  
	  
IV.II.	  The	  Selection	  of	  the	  appropriate	  VD	  formulation	  	  VD	   is	   present	   in	   many	   formulations;	   the	   two	   main	   formulations	   used	   for	   VD	  deficiency	  are	  VD2	  and	  VD3	  (Baeke,	  Takiishi	  et	  al.	  2010).	  Other	  formulations,	  such	  as	   1	   α	   hydroxycholecalciferol	   and	   1,	   25	   dihydroxycholecalciferol	   also	   exist,	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but	  are	  mainly	  used	  in	  severe	  renal	  impairement	  (British	  Medical	  Association	  and	  Royal	  Pharmaceutical	  Society	  of	  Great	  Britain	  2011).	  
Clinical	   studies	   comparing	   the	   efficacy	   of	   VD2	   supplements	   to	   VD3	   have	   yielded	  conflicting	  results.	  Some	  studies	  have	  found	  VD2	  to	  be	  as	  efficient	  as	  VD3	  in	  raising	  and	  preserving	  serum	  VD	  level	  (Holick,	  Biancuzzo	  et	  al.	  2008),	  whereas	  most	  found	  VD3	  to	  be	  more	  effective	  (Armas,	  Hollis	  et	  al.	  2004;	  Glendenning,	  Chew	  et	  al.	  2009;	  Heaney,	  Recker	  et	  al.	  2011).	  This	  could	  be	  due	  to	  the	  fact	  that	  VD2	  is	  known	  to	  have	  a	   more	   rapid	   metabolism	   and	   quicker	   clearance	   than	   VD3	   (Brown,	   Ritter	   et	   al.	  2004).	  Research	  has	  also	  shown	  VD2	  to	  have	  less	  affinity	  in	  binding	  to	  DBP	  (Hollis	  1984)	  and	  VDR	  (Houghton	  and	  Vieth	  2006),	  as	  well	  as	  a	  less	  rate	  of	  hydroxylation	  by	  25-­‐hydroxylase	  in	  the	  liver	  (Holmberg,	  Berlin	  et	  al.	  1986).	  A	  recent	  RCT	  showed	  VD2	  supplemented	  individuals	  to	  have	  a	  reduction	  in	  their	  serum	  VD	  levels	  during	  the	  winter	  months,	  wheres	  VD3	  supplemented	   individuals	  maintained	  a	  stable	  VD	  level	   throughout	   the	   six	   months	   of	   supplementation	   (Logan,	   Gray	   et	   al.	   2013).	  Similairly,	   a	   meta-­‐analysis	   of	   RCTs	   comparing	   VD2	   and	   VD3	   efficacy	   has	  recommended	  the	  use	  of	  cholecalciferol	  supplements	  for	  VD	  deficiency	  (Tripkovic,	  Lambert	  et	  al.	  2012),	  and	  is	  the	  supplement	  used	  in	  this	  study.	  
	  	  
IV.III.	  The	  Genetics	  and	  Demographics	  of	  VD	  deficiency	  	  Pigmented	   skin	   is	   considered	   a	   risk	   factor	   for	   the	   development	   of	   VD	   deficiency	  (Pearce	   and	   Cheetham	   2010).	   Several	   studies	   have	   found	   higher	   levels	   of	   VD	  deficiency	   in	   non-­‐white	   populations	   (Looker,	   Dawson-­‐Hughes	   et	   al.	   2002;	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Callaghan,	   Moy	   et	   al.	   2006).	   The	   current	   recommendations	   on	   the	   use	   of	  sunscreens,	   hats	   and	   clothing	   in	   the	   sun,	   however,	   has	   now	   placed	   the	   white	  population	  at	  comparable	  risk	  for	  VD	  deficiency	  (Pearce	  and	  Cheetham	  2010).	  	  
In	  our	   study	  population,	   both	  Caucasian	  and	  non-­‐Caucasian	  groups	  had	  a	   similar	  incidence	   of	   VD	   deficiency.	   This	   could	   be	   due	   to	   either	   our	   sample	   size,	   or	   to	  rigorous	  sun	  protection.	  
VD	   deficiency	   is	   known	   to	   run	   in	   families,	   highlighting	   a	   genetic	   link	   (Berry	   and	  Hypponen	   2011).	   This	   observation	   was	   also	   noted	   in	   our	   study.	   Research	   has	  identified	  polymorphisms	  in	  the	  VDR	  encoding	  gene,	  as	  well	  as	  the	  1	  α	  hydroxylase	  encoding	  gene	   in	  asthma	  patients	   (Raby,	  Lazarus	  et	  al.	  2004;	  Bossé,	  Lemire	  et	  al.	  2009),	   and	   in	   alopecia	   (Malloy	   and	   Feldman	   2011).	   A	   recent	   case	   control	   study	  investigated	   the	   presence	   of	   VDR	   gene	   polymorphisms	   in	   265	   AD	   patients,	   and	  found	  an	   increase	   in	  a	  specific	  VDR	  polymorphism	  in	  severe	  AD	  in	  comparison	  to	  the	  healthy	   control	   group	   (Heine,	  Hoefer	   et	   al.	   2013)	   .	   Therefore	  VDR	  could	  be	   a	  factor	   in	   AD	   development	   and	   control,	   through	   the	   effect	   of	   VD	   on	   skin	   barrier	  integrity	  and	  the	  immune	  system.	  	  
	  
IV.IV.	  VD	  deficiency	  and	  AD	  	  The	  SCORAD	   index	  was	   recently	   identified	   to	  be	   the	  most	  widely	  used	   in	   scoring	  system	   in	   RCTs	   on	   AD	   patients	   (Jones	   and	   Charman	   2011).	   To	   simplify	  interpretation	   of	   AD	   clinical	   severity,	   some	   have	   recommended	   to	   classify	   AD	  
	  
116	  
according	  to	  SCORAD	  into	  three	  categories:	  	  
mild	   (<25),	   moderate	   (25-­‐50),	   and	   severe	   AD	   (>50)	   (Oranje,	   Glazenburg	   et	   al.	  2007).	  	  
Using	  this	  system,	  VD	  levels	  have	  been	  found	  to	  be	  significantly	  higher	  in	  children	  with	   milder	   disease	   compared	   to	   patients	   with	   moderate	   and	   severe	   disease	  (Peroni,	  Piacentini	  et	  al.	  2011),	  which	   is	  confirmed	   in	  our	  study.	  SCORAD	  and	  VD	  levels	  were	   also	   significantly	   correlated	   in	   our	   study,	   similar	   to	   previous	   studies	  (Giannetti,	  Ricci	  et	  al.	  2011;	  Peroni,	  Piacentini	  et	  al.	  2011;	  Shim,	  Kim	  et	  al.	  2012).	  
In	  a	  study	  performed	  on	  patients	  with	  ages	  ranging	  from	  1	  to	  80	  years	  (mean	  age	  21),	  ADEH	  patients	  were	  shown	  to	  have	  a	  higher	  and	  more	  severe	  clinical	  scoring	  (Beck,	   Boguniewicz	   et	   al.	   2009),	   a	   finding	   that	  was	   echoed	   here.	   In	   addition,	   the	  ADEH	  children	  in	  our	  study	  were	  found	  to	  have	  significantly	  lower	  VD	  levels	  than	  AD	  children.	  	  




This	  was	  also	   found	   in	  another	  study,	  however	  no	  difference	  was	   found	   in	  LL-­‐37	  expression	   in	   non-­‐lesional	   sites	   (Hata,	   Kotol	   et	   al.	   2010).	   In	   our	   present	   study,	  ADEH	  patients	  exhibited	  reduced	  expression	  of	  baseline	  LL-­‐37	  levels	  (lesional	  and	  non-­‐lesional)	   in	   comparison	   with	   AD	   patients	   (not	   statistically	   significant).	   This	  could	  be	  due	  to	  the	  fact	  that	  the	  AD	  group	  was	  much	  smaller	  than	  the	  ADEH	  group	  (12	  vs.	  35).	  
LL-­‐37	  levels	  from	  non-­‐lesional	  sites	  did	  not	  show	  a	  significant	  difference	  between	  AD	  and	  ADEH	  patients.	  A	  possible	  explanation	  could	  be	  that	  ADEH	  patients	  could	  have	   normal	   basal	   LL-­‐37	   levels,	   but	   a	   deficiency	   in	   up	   regulation	   of	   LL-­‐37	   in	  response	  to	  injury/eczema	  lesions	  (Stahle,	  Mallbris	  et	  al.	  2008).	  
Historically,	  LL-­‐37	  levels	  taken	  from	  blood	  and	  saliva	  have	  not	  shown	  a	  difference	  in	   AD	   patients,	   or	   have	   not	   correlated	  with	   skin	   LL-­‐37	   levels,	  which	   could	  mean	  that	   the	   reduction	   of	   LL-­‐37	   observed	   in	   ADEH	   in	   lesional	   skin	   are	   skin	   specific	  (Hata,	   Udall	   et	   al.	   2007).	   A	   recent	   publication	   however,	   presented	   otherwise	  (Kanda,	  Hau	  et	  al.	  2012);	  twenty	  seven	  AD	  patients	  presented	  decreased	  circulating	  LL-­‐37	   compared	   to	   healthy	   donors,	   however	   the	   levels	   did	   not	   correlate	   with	  SCORAD.	  	  
Interestingly,	   another	   recent	   study	   found	   circulating	   LL-­‐37	   to	   increase	   with	  increased	   AD	   severity	   (Leung,	   Ching	   et	   al.	   2012),	   however	   the	   levels	   did	   not	  significantly	  differ	  from	  the	  healthy	  controls.	  Possible	  explanations	  for	  the	  different	  results	   could	  be	   that	   circulating	  LL-­‐37	  might	  not	  be	  an	  accurate	   indicator,	   as	   the	  previous	   studies	   mentioned	   before	   have	  shown	  low	  LL-­‐37	  levels	   in	   lesional	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skin	  only	  (Stahle,	  Mallbris	  et	  al.	  2008;	  Hata,	  Kotol	  et	  al.	  2010).	  Therefore	  it	  could	  be	  that	  only	  LL-­‐37	  analyzed	  from	  skin	  samples	  reflects	  accurate	  antimicrobial	  status	  of	  the	  skin.	  
In	   our	   study,	   LL-­‐37	   levels	   (both	   lesional	   and	   non-­‐lesional)	   showed	   a	   significant	  difference	  when	   stratifying	   them	  according	   to	   SCORAD,	   showing	   a	   decrease	  with	  increased	  AD	  severity.	  	  
When	  further	  differentiating	  the	  LL-­‐37	  samples	  into	  those	  taken	  from	  lesional	  and	  non-­‐lesional	  sites	  of	  our	  patients,	  no	  significant	  difference	  was	  revealed,	  although	  there	   was	   an	   observed	   trend	   of	   decreasing	   LL-­‐37	   levels	   with	   decreased	   clinical	  severity	  in	  lesional	  and	  non-­‐lesional	  skin.	  	  
Treatment	   with	   VD	   topically	   has	   been	   found	   to	   increase	   LL-­‐37	   expression	   in	  lesional	  AD	  sites	  (Stahle,	  Mallbris	  et	  al.	  2008).	  VD	  supplementation	  for	  21	  days	  at	  4000	   IU	   daily	   has	   shown	   increased	   LL-­‐37	   expression	   in	   both	   lesional	   and	   non-­‐lesional	  biopsies	  (Hata,	  Jackson	  et	  al.	  2008;	  Hata,	  Kotol	  et	  al.	  2008).	  Two	  months	  of	  VD	  supplementation	  significantly	  improved	  the	  clinical	  scoring	  in	  both	  our	  AD	  and	  ADEH	  children.	  Furthermore,	  POEM	  and	  SCORAD	  showed	  similar	  reduction	  rates	  in	  the	   clinical	   severity	   in	   our	   children	   (42.3	  %	   vs	   46.6	  %),	   reflecting	   an	   agreement	  between	   the	   two	   clinical	   tools,	   and	   indicating	   strong	   concordance	   between	  physicians	  assessment	  and	  patients	  perception	  of	  disease	  severity.	  
	  The	  LL-­‐37	  levels	  also	  increased	  significantly	  after	  VD	  treatment.	  This	  increase	  may	  account,	  at	  least	  in	  part,	  for	  the	  observed	  clinical	  improvement,	  as	  LL-­‐37	  has	  been	  known	   to	   not	   only	   act	   as	   an	   antimicrobial	   agent,	   but	   as	   an	   anti	   inflammatory	  (Kandler,	   Shaykhiev	   et	   al.	   2006),	   exhibiting	   chemotactic	   properties	   and	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inducing	  the	  production	  of	  inhibitory	  cytokines	  (Lai	  and	  Gallo	  2009).	  In	  addition,	  it	  promotes	  healthy	  wound	  development	  (Tokumaru,	  Sayama	  et	  al.	  2005;	  Park	  2008).	  
The	  observed	  clinical	  improvement	  in	  both	  groups,	  AD	  and	  ADEH,	  could	  also	  due	  to	  the	   involvement	   of	   VD	   in	   other	   processes	   in	   the	   skin	   barrier,	   such	   as	   increased	  production	  of	  structural	  proteins,	  such	  as	  filaggrin	  and	  involucrin	  (Bikle,	  Chang	  et	  al.	  2004),	   increased	  production	  of	  sphingolipids	  (Oda,	  Uchida	  et	  al.	  2009),	  and	   its	  effect	   on	   the	   calcium	   gradient	   and	   epidermal	   differentiation.	   Therefore	   VD	  supplementation	   could	   possibly	   increase	   cornified	   envelope	   formation,	   and	  maintain	  skin	  barrier	  structure	  and	  function.	  	  
It	   could	   also	   be	   due	   to	   the	   aforementioned	   effects	   of	   VD	   on	   both	   the	   innate	   and	  adaptive	  immune	  systems;	  VD	  has	  been	  shown	  to	  inhibit	  DC	  antigen	  presentation	  to	  T	  helper	   cells,	   thereby	  preventing	  over	   stimulation	  of	  T	   cells	   and	   reduction	  of	  inflammation	  (Baeke,	  Takiishi	  et	  al.	  2010).	  	  
It	   also	   seems	   to	   affect	   the	   TReg	   cell	   population	   (Dimeloe,	   Nanzer	   et	   al.	   2010).	  Therefore	  VD	  could	  have	  a	  regulatory	  effect	  on	  the	  immune	  system,	  and	  decrease	  inflammation.	  
VD	   toxicity	   is	   always	   a	   fear	   of	  most	   clinicians,	   as	   reports	   of	   toxicity	   are	   rare	   but	  could	  become	  more	  frequent	  as	  more	  people	  are	  alerted	  to	  the	  beneficial	  effects	  of	  VD	  supplementation.	  Research	  does	  show	  however,	   that	  only	   levels	  >	  250	  nmol/l	  can	   cause	   hyper-­‐calcemia	   of	  more	   than	  3.5	  mmol/l	   leading	   to	   toxicity	   symptoms	  such	   as	   fever,	   vomiting,	   weight	   loss	   and	   loss	   of	   appetite	   (Root,	   Diamond	   et	   al.	  1996).	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The	   cases	   that	   have	   been	   reported	   were	   due	   to	   either	   depot	   injections	   of	   VD	  containing	  300,000	  IU	  without	  a	  previous	  history	  of	  VD	  deficiency	  (Sezer,	  Guran	  et	  al.	  2012),	  or	  manufacturing	  errors	  of	  OTC	  supplements	   leading	   to	  an	   ingestion	  of	  up	  to	  970,000	  IU	  daily	  dose	  of	  VD	  (Araki,	  Holick	  et	  al.	  2011).	  	  In	  addition,	  previous	  trials	  done	  with	  12-­‐16	  weeks	  of	  VD	  supplementation	  at	  doses	  of	   400	   IU	   daily	   found	   their	   subjects	   still	  within	   suboptimal	   range	   (50-­‐75nmol/l)	  after	  the	  trial	  (Stellinga-­‐Boelen,	  Wiegersma	  et	  al.	  2007;	  Dong,	  Stallmann-­‐Jorgensen	  et	  al.	  2010).	  	  
Long-­‐term	  supplementation	  with	  high	  doses	  of	  VD	  (2000	  IU/d)	  was	  tolerated	  well	  with	  no	  incidence	  of	  VD	  toxicity,	  and	  VD	  levels	  remained	  in	  the	  normal	  range	  (90-­‐145	  nmol/l)	  (Maalouf,	  Nabulsi	  et	  al.	  2008).	  
	  After	   two	  months	   of	   VD	   supplementation	   in	   our	   study,	   VD	   levels	   also	   showed	   a	  significant	  increase,	  however	  remained	  within	  normal	  levels.	  In	  addition,	  although	  serum	  calcium	   levels	  showed	  a	  significant	   increase,	   the	  mean	   level	   still	   remained	  within	  normal	  range.	  	  Another	   point	   to	   consider	   is	   the	   optimal	   VD	   levels	   needed	   for	   various	   health	  outcomes.	   Research	   has	   shown	   that	   levels	   <	   100	   nmol/l	   are	   associated	   with	   a	  reduction	  of	  pancreatic	  responsiveness	  to	  insulin	  (Chiu,	  Chu	  et	  al.	  2004).	  Levels	  <	  80	   nmol/l	   were	   associated	   with	   an	   increase	   in	   colorectal	   cancer	   risk	   (Gorham,	  Garland	  et	  al.	  2007),	  as	  well	  as	  an	   increased	  risk	  of	  periodontal	  disease	  (Dietrich,	  Joshipura	  et	  al.	  2004).	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A	  meta-­‐analysis	  conducted	  on	  multiple	  health	  outcomes	  recommended	  the	  optimal	  level	  of	  VD	  to	  be	  in	  the	  range	  of	  90-­‐100nmol/l	  (Bischoff-­‐Ferrari,	  Giovannucci	  et	  al.	  2006).	  To	  date,	  however,	  no	  research	  has	  been	  done	  on	  the	  optimal	  levels	  for	  AD.	  	  The	  role	  of	  VD	  in	  atopic	  disorders,	  since	  they	  are	  primarily	  Th2	  driven	  (Zheng,	  Yu	  et	  al.	  2011),	  has	  produced	  conflicting	  results,	  showing,	  as	  mentioned	  previously,	  both	  induction	   (Boonstra,	   Barrat	   et	   al.	   2001)	   and	   suppression	   (Staeva-­‐Vieira	   and	  Freedman	   2002)	   of	   the	   Th2	   cell	   population	   in	   vitro.	   Hyponnen	   et	   al	   (2009)	   in	   a	  recent	   study	   found	   atopic	   patients	  with	   excessively	   high	   (>135nmol/L)	   and	   very	  low	  VD	  levels	  (<25nmol/)	  were	  associated	  with	  high	  serum	  IgE	  levels.	  	  	  Our	   study	  does	  not	   show	  a	   significant	   change	   in	   total	   serum	   IgE	   levels	   after	   two	  months	  of	   treatment	  with	  VD,	  which	   could	  mean	   that	   supplementation	  of	  people	  with	  low	  VD	  would	  not	  dramatically	  change,	  but	  improve,	  the	  allergic	  state	  of	  AD	  or	  ADEH	  patients	  by	  returning	  VD	  to	  healthy	  levels.	  	  	  As	  it	  was	  a	  practice	  evaluation	  study	  all	  medications,	  oral	  and	  topical,	  continued	  as	  normal	  with	  no	  constraints,	  which	  is	  a	  limitation	  in	  our	  study.	  Another	  drawback,	  for	   the	   same	   reason,	   is	   that	   the	   AD	   patients	   with	   normal	   VD	   levels	   were	   not	  followed	  for	  clinical	  scoring	  as	  well,	  to	  allow	  for	  unknown	  factors,	  which	  could	  be	  contributing	   to	   the	   clinical	   improvement	   of	   the	   VD	   deficient	   AD	   patients.	  Nevertheless,	  the	  extremely	  significant	  results	  of	  VD	  supplementation	  in	  this	  study,	  renders	  that	  possibility	  unlikely.	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V. Future	  work:	  
	  	  This	   thesis	   has	   answered	   several	   questions,	   however	   has	   raised	   many	   more.	  Several	  areas	  could	  be	  explored	  further	  such	  as:	  
- An	  audit	  to	  determine	  the	  true	  prevalence	  of	  VD	  deficiency	  in	  AD	  children,	  with	  a	  sample	  size	  of	  at	  least	  250	  patients.	  
- A	   cross	   sectional	   study	   to	   determine	   the	   prevalence	   of	   VD	   deficiency	   in	  healthy	  children	  in	  the	  UK.	  
- A	   genetic	   epidemiological	   study	   of	   our	   VD	   deficient	   AD	   children	   to	  determine	  the	  presence	  of	  VDR	  polymorphisms,	  as	  well	  as	   the	  presence	  of	  other	  polymorphisms	  in	  the	  VD	  processing	  enzymes.	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